Pharmacology of Gemcitabine in the Asian Population by WANG LINGZHI
                                                                                                                                                                              
 
 
Pharmacology of Gemcitabine  





Wang Ling Zhi 






 Pharmacology of Gemcitabine  




Wang Ling Zhi 
(M.Sc. National University of Singapore) 
 
A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF 
PHILOSOPHY 
 
DEPARTMENT OF PHARMACOLOGY 







I would like to express my sincere thanks to my supervisors, A/Prof. Goh Boon Cher and 
A/Prof. Lee How Sung for their great supervision, invaluable advice and immense 
patience during this tough and happy time in pursuing my Ph.D. degree. 
 
My deepest gratitude goes to A/Prof. Chan Sui Yung for her consistent encouragement! 
 
I acknowledge excellent advice and suggestions from my Ph.D. qualified examination 
committee, A/Prof. Peter Wong, A/Prof. Paul Ho and Prof. Philip Moore. 
 
I’m grateful to my lab mates, collaborators as well as friends for their great help: 
Dr Tham Lai Sam, Mr Guo Jia Yi, Ms Khoo Yok Moi, Ms Fan Lu, Ms Yap Hui Ling and 
Ms Wan Seow Ching from NUS-NUH Pharmacokinetics and Pharmacogenetics Lab. 
Dr Ross Soo, Dr Lee Soo Chin, Dr Yong Wei Peng and Ms Ong Ai Bee from TCI, NUH. 
Dr Richie Soong from ORI, NUS for his kind help on pharmacogenetic screening. 
Dr Luo Nan, Dr Han Yi and Xiang Xiao Qiang for their great help and support! 
 
I would also like to extend my gratitude to Dr Lim Hong Liang and Dr Robert Lim for 
providing financial funding on my first two years’ study and Singapore NMRC for 
providing Scientist Award to support my Ph.D. Training. 
 








TABLE OF CONTENT 
ACKNOWLEDGEMENTS           I 
TABLE OF CONTENTS            II 
LIST OF TABLES            X 
LIST OF FIGURES          XII 
ABBREVIATION          XV 
LIST OF PUBLICATIONS        XVII 
SUMMARY          XVIII 
Chapter One: Literature Review                1 
1.1 Introduction of Gemcitabine            2 
1.2 Chemistry and Formulation of Gemcitabine          2 
1.3 Bio-analyses of Gemcitabine and its Metabolites          4 
 1.3.1. Quantification of dFdC and dFdU in Human Plasma       5 
 1.3.2. Quantification of dFdCTP in White Blood Cells        6 
1.4 Pharmacokinetics of Gemcitabine           7 
 1.4.1. Distribution, Metabolism and Excretion         7 
 1.4.2. Pharmacokinetic Parameters of Gemcitabine        8 
1.5 Pharmacodynamics of Gemcitabine          10 
 1.5.1 Mechanism of Action           10 
  1.5.1.1 Reduction of DNA Synthesis        10 
  1.5.1.2 Ribonucleotide Reductase Inhibition       11 
  1.5.1.3 Poisoning Topoisomerase I         11 
  III
  1.5.1.4 Self-Potentiation         12 
 1.5.2 Molecular Pharmacology of Gemcitabine       14 
1.6 Pharmacogenetics of Gemcitabine         14 
1.6.1 Genetic Pathway in Gemcitabine Metabolism      14 
1.6.2 Identification and distribution of SNP       16 
1.7. Toxicity of Gemcitabine           16 
 1.7.1 Non-hematology Toxicity         16 
 1.7.2 Hematology Toxicity          17 
 1.7.3 Models for Gemcitabine-induced Neutropenia       17 
1.8. Preclinical Research of Gemcitabine         18 
1.8.1 In vitro Studies           18 
1.8.2 In vivo Studies           19 
1.9. Clinical Uses of Gemcitabine          20 
 1.9.1 Single-agent Gemcitabine         21 
  1.9.2 Gemcitabine plus Platinium Compounds       21 
 1.9.3 Gemcitabine plus non-platinium agents       23 
1.10 Nucleoside Transporters          23 
 1.10.1. Effect of Nucleoside Transporters on Activity of Gemcitabine    24 
 1.10.2. Effect of Nucleoside Transporters on Excretion of Gemcitabine    24 
1.11 Chemoresistance of Gemcitabine         26 
1.12 Summary            27 
Chapter Two: Bioanalytical Method Development for Determination of  
Gemcitabine and Its Metabolites        29 
  IV
2.1. Introduction            30 
2.1.1. Quantification of dFdC and dFdU in human plasma using  
          LC-MSMS                      30 
 2.1.2. Ion-exchange HPLC determination of dFdCTP in human WBC     33 
2.2. Objectives            34 
2.3. Materials and Methods           34 
2.3.1. Reagents and Standards          34 
2.3.2. Sample Collection and Pretreatment        34 
  2.3.2.1. Plasma Sample Preparation       35 
  2.3.2.2. Blood Cell Preparation        35 
   2.3.2.2.1. WBC Isolation        35 
   2.3.2.2.2. Storage of Cell Samples       36 
   2.3.2.2.3. Pre-analytical Preparation of WBC Samples    36 
2.3.3. Instrumentation          37 
2.3.3.1. HPLC-MS/MS (dFdC and dFdU)       37 
2.3.3.2. HPLC-UV (intracellular dFdCTP)      38 
2.3.4. Standard Solutions and Calibration Curves     38 
2.3.4.1. Gemcitabine and dFdU       38 
2.3.4.2. Gemcitabine Triphosphate (dFdCTP)     39 
2.3.5. Validation Description        40 
2.3.5.1. Gemcitabine and dFdU in plasma      40 
2.3.5.2. Matrix effect evaluation       41 
2.3.5.3. Gemcitabine Triphosphate in the Cell     42 
  V
2.4. Results and Discussion           42 
2.4.1. Gemcitabine and dFdU in Human Plasma       42 
2.4.1.1. Chromatographic Separation       42 
2.4.1.2. Method Validation of dFdC and dFdU      45 
2.4.2. Gemcitabine Triphosphate         50 
2.4.2.1. Chromatographic Separation       50 
2.4.2.2. Standard Curve of dFdCTP       50 
2.4.2.3. Optimization of dFdCTP extraction from human WBC    52 
2.5. Conclusions            55 
Chapter Three: In vitro Study of Gemcitabine as a Single Agent or  
     Combination Therapy              56 
3.1. Introduction            57 
3.2. Objectives            59 
3.3. Materials and Methods           59 
3.3.1. Drug and chemicals          59 
3.3.2. Cell lines and cell culture         60 
3.3.3. Growth inhibition study         60 
3.3.4. dFdCTP and dFdC quantitation        61 
3.3.4.1. dFdC sampling and preparation       61 
3.3.4.2. Cell harvesting and preparation        62 
3.3.5. Titration of gemcitabine concentration for maxium  
accumulation of dFdCTP         63 
3.3.6. Combination Study          63 
  VI
3.3.7. DNA content measurement          64 
3.4. Results and Discussion            65 
3.4.1. Gemcitabine’s chemical stability in culture medium without cells    65 
3.4.2. Gemcitabine’s sensitivity on NPC cell lines        66 
3.4.3. Impact of incubation time on IC50 of gemcitabine for HK1     66 
3.4.4. Effect of incubation time and concentration of dFdC on  
intracellular accumulation rate of dFdCTP using HONE1  
cell model                  68 
3.4.5. Effect of dFdC concentration on cell viability with an  
increasing exposure time             71 
3.4.6. Combination of gemcitabine with PXD101        72 
3.4.6.1. CNE1 cell model          73 
3.4.6.2. H292 cell model          73 
3.4.6.3. H1299 cell model          78 
3.5. Conclusions              85 
Chapter Four: Pharmacokinetics & Pharmacodynamics of Fixed Dose Rate 
Infusion of Gemcitabine in Combination with Carboplatin in NSCLC       86     
4.1. Introduction              87 
4.2. Objectives              88 
4.3. Methodology              88 
4.3.1. Patient selection            88 
4.3.2. Treatment plan             89 
4.3.3. Patient evaluation            92 
4.4. Results                93 
  VII
4.4.1. Patient Characteristics            93 
4.4.2. Toxicity              95 
4.4.3. Response              98 
4.4.4. Pharmacokinetic data             98 
4.5. Discussion               100 
4.6. Conclusions               103 
Chapter Five: Pharmacokinetics & Pharmacodynamics of Gemcitabine at Two 
 Infusion Rates in Combination with Carboplatin in NSCLC       104 
5.1. Introduction               105 
5.2. Objectives of the study              106 
5.3. Methodology               107 
 5.3. 1. Patient selection             107 
 5.3.2. Treatment Plan             107 
 5.3.3. Patient Evaluation             108 
 5.3.4. Response               109 
 5.3.5. Pharmacokinetic Analysis            110 
  5.3.5.1. Plasma dFdC and dFdU levels          110 
  5.3.5.2. Intracellular dFdCTP levels          112 
  5.3.5.3. Pharmacokinetic calculation          113 
5.3.6. Statistics              114 
5.3.7. Hematological toxicity modeling           115 
5.4. Results                 116 
5.4.1. Patient characteristics            116 
5.4.2. Treatment               117 
  VIII
5.4.3. Toxicity            117 
5.4.4. Efficacy            119 
5.4.4.1. Response Rate and Survival        119 
5.4.4.2. Early Phase Tumor Response        120 
5.4.5. Pharmacokinetic data           120 
  5.4.5.1. Non-compartmental Anaysis        120 
  5.4.5.2. Compartmental Anaysis on gemcitabine plasma level     124  
 5.4.6. Hematological models           126 
5.4.7. Correlation of dFdU/gemcitabine ratios with demography &  
          tumor shrinkage           128 
5.5. Discussion             132 
5.5.1. Phase II pharmacokinetic study of gemcitabine dosing  
10 mg/m2/min for 75 min or 1000 mg/m2 for 30 min      132 
 5.5.2. Phase II pharmacodynamics and toxicities of gemcitabine  
dosing 10 mg/m2/min for 75 min or 1000 mg/m2 for 30 min     133 
5.5.3. Early phase progression marker for non-responders to  
gemcitabine treatment in NSCLC         135 
5.6. Conclusions             137 
Chapter Six: Genotypic and Phenotypic Association of Gemcitabine in Asian  
Non-Small Cell Lung Cancer Patients        138 
6.1. Introduction             139 
6.2. Objectives             140 
6.3. Patients and Methods            141 
  IX
6.3.1. Study population           141 
6.3.2. Blood Sampling          141 
6.3.3. Quantitation of dFdCTP and Pharmacokinetic analysis     142 
6.3.4. Selection of SNP loci          142 
6.3.5. Pharmacogenetic analysis         142 
6.3.6. Statistics           143 
6.4. Results             144 
6.4.1. Distribution of gemcitabine pathway genotypes in healthy 
  Caucasians and Asians         144 
  
6.4.2. Impact of hCNT2 Polymorphism on Neutropenia      147 
 
6.4.2.1. The Effect of Sex on Pharmacokinetics of Gemcitabine     149 
6.4.2.2. Phenotypic and Genotypic analysis      149 
 6.5. Discussion           154 
6.6. Conclusions            157 
 
Chapter Seven: Conclusions              158 






LIST OF TABLES 
Table No.    Description                  Pages 
Table 1.1 Reported Pharmacokinetic Parameters of Gemcitabine        9 
Table 2.1 Calibrator Preparation           39 
Table 2.2 Intra- and inter-day precision and accuracy for dFdC and dFdU   45 
Table 2.3 Matrix effect and recovery tested in patient control plasma at  
two concentration levels           46 
Table 2.4  dFdCTP method development and validation using HONE1      52 
Table 3.1 Culture media sampling time point for determination of dFdC      61 
Table 3.2 IC50 of gemcitabine to NPC after 72 h incubation        66 
Table 3.3 IC50 of gemcitabine, PXD101 or in combination on H1299  
after 72 h              81 
Table 4.1 Karnofsky performance scale and explanation        94 
Table 4.2 Cycle 1 hematologic toxicities by dose level (n = 15)       96 
Table 4.3 Cumulative grade 3/4 hematologic toxicities by dose level      96 
Table 4.4 Non-hematologic toxicity (n = 15)          97 
Table 4.5 Pharmacokinetic parameters of plasma dFdC        98 
Table 4.6 Reverse effect of dosage of gemcitabine and frequencies of severe 
neutropenia (grade 3/4)          102 
Table 5.1  RECIST response criteria for evaluation of target lesions     109 
Table 5.2        PK form of infusional gemcitabine         111 
Table 5.3 Patient characteristics          116 
Table 5.4 Hematologic toxicities           118 
  XI
Table 5.5 Non-hematologic toxicities for grade 3 or 4 (% of patients)     118 
Table 5.6 Pharmacokinetic parameters of (A) plasma gemcitabine and (B) 
intracellular gemcitabine triphosphate                   121 
Table 5.7       Plasma concentration ratio of dFdU/gemcitabine in  
                        NSCLC patients           124 
Table 5.8 Difference of Pharmacokinetic parameters of plasma gemcitabine 
between    arm A (75-min infusion) and arm B (30-min infusion)   125 
Table 5.9 Arm B Univariate linear regression of covariates tested  
with the lnANCnadir_all          126 
Table 5.10 Arm B Univariate linear regression of covariates tested  
with the lnPLTnadir_all          127 
Table 5.11     Effect of demographic factors on plasma concentration  
ratio of dFdU versus gemcitabine          128 
Table 5.12    Relationship between responders and plasma concentration  
                      ratio of dFdU versus gemcitabine         129 
Table 6.1 Primers, PCR annealing temperatures and dispensation  






LIST OF FIGURES 
Figure No.    Description                  Pages 
Figure 1.1 The Chemical Structure of Gemcitabine            2 
Figure 1.2 Activation Pathways of Gemcitabine           13 
Figure 1.3 Metabolism pathway of gemcitabine to its active metabolites     
dFdCDP and dFdCTP                  15 
Figure 2.1 The chemical structures of dFdC, dFdU and Internal Standard        32 
Figure 2.2 The chromatograms of dFdC (upper) and dFdU (lower) at LLOQ 
 in human plasma sample              44 
Figure 2.3 Standard Curve for dFdC (upper, n = 3) and dFdU (lower, n = 3)      48 
Figure 2.4 HPLC chromatogram of dFdCTP in Human Sample Analysis         50 
Figure 2.5 Standard Curves of dFdCTP                    51 
Figure 2.6 Stability of dFdCTP in solution of HClO4 (0.4M)           51 
Figure 2.7 Stability of dFdCTP in mixture solution of HClO4 (0.4M) 
   and KOH (0.4M) (1:1)              52 
Figure 2.8 Stability of dFdCTP in mixture solution of HClO4 (0.4M) 
and KOH (0.8M)               52 
Figure 3.1 Determination of gemcitabine stability in culture medium        65 
Figure 3.2 Effect of exposure time on the inhibition of HK1 by gemcitabine      67 
Figure 3.3 Effect of exposure time on the accumulatin of dFdCTP in  
HONE1 with various concentrations of gemcitabine          69 
Figure 3.4 Kinetics of dFdC in culture medium for variable  
incubation concentrations of gemcitabine (upper: full  
  XIII
concentration scale; lower: enlarged concentration below 5 µM)      70 
Figure 3.5 The influence of incubation time and concentration of  
gemcitabine on the viability changes of HONE1           72 
Figure 3.6 IC50 of gemcitabine to CNE1 with PXD101 (2 µM) after 72 h         73 
Figure 3.7 IC50 of gemcitabine alone to H292 (upper) and IC50 of  
gemcitabine combined with PXD101 (2.5 µM) (lower)          75 
Figure 3.8 Microscope observation on H292 treated with indicated  
concentrations of gemcitabine, PXD101, or both after 72 h          76 
Figure 3.9 Flowcytometry of H292 treated with indicated drugs          77 
Figure 3.10 IC50 of PXD101 on H1299 after 72 h incubation           79 
Figure 3.11 IC50 of gemcitabine combined with 1.6 µM of PXD101  
on H1299 after 72 h incubation             80 
Figure 3.12 Microscope observation on H1299 treated with indicated 
concentrations of gemcitabine, PXD101, or both after 72 h          82 
Figure 3.13 Flowcytometry of H1299 treated with indicated drugs          83 
Figure 3.14 Cell cycle changes of H1299 treated with gemcitabine alone  
or in combination of gemcitabine and PXD101           84 
Figure 4.1 Treatment doses of gemcitabine             90 
Figure 4.2 Plots of time agaist mean gemcitabine and dFdU concentrations 
 with 75-min and 90-min infusions of gemcitabine (10 mg/m2/min)    99 
Figure 4.3    Correlation of toxicity rate (%) and dosage of gemcitabine                 102 
Figure 5.1 Progression free survival            119 
Figure 5.2 The pharmacokinetic profile of gemcitabine and dFdU in plasma   122 
  XIV
Figure 5.3 The pharmacokinetic profile of dFdCTP in PBMC       123 
Figure 5.4 Association of thrombocytopenia with dFdCTP exposure  
for arm B             127 
Figure 5.5 Box plot of response vs concentration ratio of dFdU and  
gemcitabine at two hour after infusion         129 
Figure 5.6  Frequency histogram for the concentration ratio of  
dFdU/gemcitabine at 120 min           130 
Figure 6.1 Selection of Gene loci involved in pathways of gemcitabine  
transport, metabolism and activity from an extensive  
search of publications and genome databases          144 
Figure 6.2 Difference in sequence variants distribution between 94 healthy 
Asians and Caucasians                  146 
Figure 6.3 Effect of gender on neutrophil nadir to gemcitabine treatment       148 
Figure 6.4 SNPs distribution between males and females             150 
Figure 6.5 Association of SLC28A2+65 C>T (left) and SLC28A2+225 C>A 
(right) with neutrophil nadir                  150 
Figure 6.6 Association of SLC28A2+65 C>T (left) and  
SLC28A2+225 C>A (right) with survival              151 
Figure 6.7 Comparison between neutropenia grade and frequency  
of all subjects (n = 53)           153 
Figure 6.8  Comparison between neutropenia grade and frequency  
within the cohort expressing S28A2+225 (C>A) (n = 17)        153 
 
  XV
Abbreviations   
AIC: Akaike Information Criterion; 
ANC: absolute neutrophil count; 
AUC: area under the concentration-time curve; 
BSA: body surface area; 
CBC: complete blood count; 
CDA: cytidine deaminase; 
CNT: concentrative nucleoside transporters; 
CR: complete response; 
CT: computed tomography; 
DCTD: deoxycytidylate deaminase; 
dCK: deoxycytidine kinase;  
dFdC : 2’-deoxy-2’, 2’-difluorocytidine; 
dFdCDP: gemcitabine diphosphate; 
dFdCMP: gemcitabine monophosphate; 
dFdCTP: gemcitabine triphosphate; 
dFdU: 2’-deoxy-2’, 2’-difluorouridine; 
dFdUMP: difluorodeoxyuridine monophosphate; 
ENT: equilibrative nucleoside transporters; 
ITT: intent-to-treat; 
KPS: Karnofsky performance status; 
LC-MSMS: liquid chromatography tandem mass spectrometry; 
LOD: limit of detection; 
  XVI
LLOQ: low limit of quantitation; 
NCA: non-compartmental analysis; 
NPC: nasopharyngeal carcinoma; 
NSCLC: non-small cell lung cancer; 
NTs: Nucleoside Transporters; 
PBMCs: peripheral blood mononuclear cells; 
PCR: polymerase chain reaction; 
PD: pharmacodynamics; 
PD (tumor response): progressive disease; 
PK: pharmacokinetics; 
PLT: Platelet Count Nadir; 
PR: partial response; 
QC: quality control; 
RDI: relative dose intensity; 
RRM1: ribonucleotide reductase M1; 
RRM2: ribonucleotide reductase M2; 
SCCHN: squamous cell carcinoma of the head and neck; 
SD: stable disease; 
SNP: single nucleotide polymorphism; 
TTP: time to progression; 
TYMS: thymidylate synthase; 
ULN: upper limit of normal; 
WBC: white blood cell; 
  XVII
LIST OF PUBLICATIONS & ABSTRACTS 
1. Wang LZ, Goh BC, Lee HS, Noordhuis P, Peters GJ. THERAPEUTIC DRUG 
MONITORING 25 (2003): 552-557. 
2. Soo RA, Lim HL, Wang LZ, Lee HS, Millward MJ, Tok LT, Lee SC, Lehnert M, Goh 
BC. CANCER CHMOTHER PHMACOL.52 (2003): 153-158. 
3. Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, Lee HS, Millward M, 
Liang S, Beale P, Lee SC, Goh BC. ANNALS OF ONCOLOGY 17 (2006): 1128-1133. 
4. Tham LS, Wang LZ, Soo RA, Lee HS, Lee SC, Goh BC, Holford NH. CANCER 
CHMOTHER PHMACOL. 2008 Feb 28. 
5.  Tham LS, Wang LZ, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, and Holford NH. 
Clinical Cancer Reseach. 14 (2008): 4213-4218.     
6. Ma B (Ma, Brigette), Goh BC (Goh, Boon Cher), Tan EH (Tan, Eng Huat), Lam KC 
(Lam, Kwok Chi), Soo R (Soo, Ross), Leong SS (Leong, Swan Swan), Wang LZ (Wang, 
Ling Zhi), Mo F (Mo, Frankie), Chan ATC (Chan, Anthony T. C.), Zee B (Zee, Benny), 
Mok T (Mok, Tony). INVESTIGATIONAL NEW DRUGS 26 (2008): 169-173. 
7. Ross A. Soo, Ling Zhi Wang, Swee Siang Ng, Pei Yi Chong, Wei Peng Yong, Soo 
Chin Lee, Jian Jun Liu, Tai Bee Choo, Lai San Tham, How Sung Lee, Boon Cher Goh, 
Richie Soong. Lung Cancer (2008) June 4. 
 
Conference Abstracts: 
1. Ling-Zhi Wang,1,2 Wei-Peng Yong,1 Lai-San Tham,1 Theresa-May-Chin Tan,3 Ross-A. 
Soo,1 Soo-Chin Lee1, Boon-Cher Goh,1,2 How-Sung Lee2* Micro Protein Precipitation 
with Negligible Matrix Effect for Rapid Determination of Gemcitabine and Its Metabolite 
in Human Plasma by LC/MS/MS. AAPS Annual Meeting 2008. 
AAPS Award Winner (AAPS is abbreviation of American Association of Pharmaceutical 
Scientists). 
2. LZ Wang1, 2, RA Soo1, WP Yong1, LS Tham1, SC Lee1, HS Lee2, BC Goh1, 2 
Correlation between Plasma Metabolite vs Gemcitabine Ratios and NSCLC Non-





Gemcitabine (dFdC) is a broad spectrum antimetabolite effective for treating non-small 
cell lung cancer (NSCLC), breast cancer and nasopharyngeal cancer (NPC). Its complex 
disposition pathway and treatment schedule dependence provide a unique opportunity to 
investigate pharmacokinetic and pharmacodynamic interactions, including their genetic 
determinants in order to optimise clinical use.  
Firstly, the progress in gemcitabine research was reviewed with respect to its chemical 
structure, formulation and clinical application. This is followed by a discussion on the 
current status and the recent development in pharmacokinetics, pharmacodynamics and 
pharmacogenetics of gemcitabine. The possible drug resistance mechanisms were 
analyzed including the important aspects of gemcitabine intracellular transporters and 
metabolic enzyme activities. A novel potential combination chemotherapy was proposed 
based on the significant synergistic effect between gemcitabine and PXD101, a HDAC 
inhibitor.  
Validated analytical methods were developed to provide an important research platform 
for clinical study of gemcitabine. These included 1) a 16-fold improved sensitivity LC-
MSMS methodology which was validated and applied to Phase II clinical sample 
quantification of gemcitabine and its deaminated metabolite; 2) a more efficient 
quantitation of intracellular dFdCTP (gemcitabine triphosphate) which is the main active 
form of gemcitabine inside the cells. 
Sensitivity of NPC and NSCLC tumour cell lines to gemcitabine and the novel 
combination of gemcitabine with PXD101 were tested. In vitro experiments suggested 
that the duration of incubation would be the primary determinant of intracellular dFdCTP 
  XIX
accumulation when the real time concentration of dFdC was ≥ 2 µM.  A plateau 
concentration of intracellular dFdCTP was achieved after 8 h incubation with initial 
concentration above 10 µM dFdC. On the other hand, the cell viability was of the same 
magnitude with 48 h incubation when the initial exposure concentration of dFdC was ≥ 
10 µM. The resultant viability was consistent with the combined effect of dFdCTP 
accumulation level and retention duration (incubation time). Potent synergistic 
cytotoxicity was obtained even with different cell models especially with p53-null cell 
line (H1299) (Combination Index = 0.5001) when PXD101 was added to gemcitabine.  
Pharmacokinetics and pharmacodynamics of a fixed dose rate infusion of 10 mg/m2/min 
of gemcitabine was studied in human subjects. The result suggested that the target plasma 
gemcitabine concentration above 10 µM could be achieved after 75 min infusion of 
gemcitabine at a constant rate of 10 mg/m2/min. Pharmacokinetic comparison between a 
fixed dose rate infusion of 10 mg/m2/min of gemcitabine and standard 30-min infusion of 
1000 mg/m2 was conducted. Despite a 25% lower total dose of gemcitabine at an infusion 
rate of 10 mg/m2/min in combination with carboplatin in NSCLC, a similar clinical 
efficacy and safety profile was achieved compared to the standard 30-min infusion 
regimen. Pharmacokinetic analyses of gemcitabine and dFdCTP suggest that the 30-min 
infusion is a pharmacologically less efficient compared to a fixed dose rate of 10 
mg/m2/min. In addition, we found that intracellular dFdCTP exposure predicts 
myelosuppression in the 30-min infusion regimen but it is not useful for tumour response.  
Plasma metabolite/parent ratios at 120 min were found to be associated with the early 
phase (after 2nd cycle) tumor shrinkage. Briefly, the ratios of dFdU/gemcitabine for 
nonresponders were significantly higher than those of the responders according to 
  XX
RECIST criteria. There would be as high as 95% probability in predicting non-responders 
to infusion gemcitabine in combination with carboplatin as long as the ratios were ≥ 500 
due to fast deamination of gemcitabine. This finding has provided a useful marker in 
evaluating the efficacy of gemcitabine at an early phase of chemotherapy. 
Genetic variants in transporter hCNT2 (SLC28A2+65 C>T and SLC28A2+225 C>A) 
were identified as a potential determinant of neutropenia and patient survival in the 
gemcitabine-carboplatin combination treatment. These genotypic variants were 
significantly associated with increased hematological toxicity, response and survival in 
Asian patients with advanced non-small cell lung cancer (NSCLC) receiving gemcitabine 
based chemotherapy.  
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1.1 Introduction of Gemcitabine 
Gemcitabine hydrochloride (Gemzar®) was approved by FDA in 1996 as a novel 
anticancer agent in advanced or metastatic pancreatic cancer. Initially, gemcitabine, 2’-
deoxy-2’, 2’-difluorocytidine (dFdC), was investigated for its antiviral effects. However, 
this novel deoxycytidine analogue showed a high potential in cancer management, 
especially in solid tumors.[1] The gemcitabine chemical structure, formulation, 
pharmacokinetics, pharmacodynamics and pharmacogenetics  will first be reviewed. 
 
1.2 Chemistry and Formulation of Gemcitabine 
The anti-metabolite gemcitabine is a nucleoside pyrimidine analogue that has been used 
clinically as an anticancer drug for more than ten years. The chemical structure of 
gemcitabine is shown in Figure 1.1 in which the hydrogens on the 2’ carbon of 
deoxycytidine are replaced by fluorides. Its molecular weight is 263.1 and its pKa is 3.6. 




Figure 1.1 The Chemical Structure of Gemcitabine 
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It is marketed as Gemzar® by Eli Lilly. The nonpropietary name is gemcitabine 
hydrochloride and the Lilly compound number is LY188011 HCl. The chemical 
nomenclature is 2’-deoxy-2’, 2’-difluorocytidine monohydrochloride. The drug is a 
lyophilized product comprising of the equivalent of 200 or 1000 mg of gemcitabine free 
base and the inactive ingredients mannitol, sodium acetate, and water for injection. The 
drug is stable at room temperature. 
As a prodrug, gemcitabine exerts its anticancer activity after a rate limiting 
phosphorylation to gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate 
(dFdCTP) intracellularly by deoxycytidine kinase (dCK). Only 10% of gemcitabine is 
converted into its active dFdCDP and dFdCTP due to a fast and extensive deamination by 
cytidine deaminase (CDA) in blood, liver, kidney and other tissues to the inactive 
metabolite 2’-deoxy-2’, 2’-difluorouridine (dFdU) which will be excreted mainly in the 
urine. This rapid deamination also resulted in a very short half life (about 15 min) of 
gemcitabine in human blood. In order to overcome this, biopharmaceutical scientists have 
attempted to increase the efficacy of gemcitabine through chemical modification, 
formulation optimization as well as targeting delivery system. [2-5] 
Several series of gemcitabine derivatives have been synthesized. Among these 
compounds, esters or amides of gemcitabine derivatized by conjugating saturated and 
monounsaturated 18–20 carbon atom chains to the 3- and/or 5-OH and/or the 4-amino 
group showed improved cytotoxic activity than the parent drug.[6] Peripheral 
benzodiazepine receptors (PBRs) were selected as targets to selectively enhance 
gemcitabine delivery through a PBR ligand-drug conjugates due to the overexpression of 
PBRs in brain tumors compared to normal brain tissues.[7] Recently, a series of 
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increasingly lipophilic prodrugs of gemictabine were synthesized by linking the 4-amino 
group with valeroyl, heptanoyl, lauroyl and stearoyl linear acyl derivatives. These 
compounds were further developed into liposomes, prolonging their plasma half-life and 
increasing intracellular release of the free drug.[8] Gemcitabine-loaded liposomes were 
tested in human anaplastic thyroid carcinoma cells.[9] The results showed that liposome 
encapsulated gemcitabine has improved cytotoxicity at a lower concentration and shorter 
exposure time when compared to free gemcitabine. Liposome encapsulated gemcitabine 
promises to be an exciting alternative to clinicians considering lower doses and reduced 
toxicity.  
 
1.3 Bio-analyses of Gemcitabine and its Metabolites  
Gemcitabine is used in combination with cisplatin for the treatment of advanced non-
small cell lung cancer (NSCLC) in the first-line setting.[10, 11] Gemcitabine inhibits DNA 
synthesis through its intracellular phosphorylated metabolites, dFdCDP and dFdCTP.[12, 
13] Many new gemcitabine combinations are being tested in clinical trials to find the 
relationship between response rates, toxicities and pharmacokinetic profiles as well as 
genetic variants, including Asian patients.[14, 15] Even though gemcitabine is a prodrug, its 
plasma concentrations have been reported to be closely related to accumulation rate of its 
intracellular therapeutically active phosphate metabolites.[16] Hence, monitoring of 
gemcitabine and its intracellular metabolite concentrations is important for 
pharmacokinetic and pharmacodynamic study of gemcitabine and will result in 
pharmacologically guided individualized treatment in the clinical setting. 
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1.3.1 Quantification of dFdC and dFdU in Human Plasma 
After i.v. administration, gemcitabine is converted rapidly in the plasma to the inactive 
product dFdU by CDA. Hence, plasma quantification of dFdC is difficult because this 
prodrug has an extremely short half-life. [17] Metabolism and elimination of the drug is 
rapid and highly variable. Like most other anti-cancer drugs, gemcitabine has a narrow 
therapeutic index. The principle dose-limiting toxicity of gemcitabine therapy is 
myelosuppression. It is therefore critical to develop a simple and sensitive quantitative 
method to quantify dFdC for evaluation of the pharmacokinetic and pharmacodynamic 
profiles of gemcitabine in clinical trials. This method can be utilized for therapeutic drug 
monitoring as well. Furthermore, simultaneous quantitation of dFdU is necessary for us 
to understand the pharmacokinetic profile of the parent drug even though dFdU is 
regarded as inactive metabolite but may contribute to gemcitabine toxicity. [18] Several 
assays have been described for determination of gemcitabine and dFdU in plasma, urine 
and tissue using reversed-phase HPLC with or without ion-pair reagents. [19-26] Currently, 
the most sensitive assay using HPLC-UV is a normal-phase HPLC system.[27] A 0.05 
μg/ml limit of quantitation for both dFdC and dFdU was achieved in the assay. However, 
its tedious sample preparation limits its application in monitoring clinical samples. 
So far, several simultaneously analytical methods have been published for quantification 
of dFdC and dFdU in plasma, urine and tissues using high-performance liquid 
chromatography coupled with UV detection. However, it is very difficult to monitor the 
very low parent drug concentrations at later sampling points during the elimination phase 
because of, firstly, rapid decline of dFdC plasma concentration after the end of infusion 
and secondly the limitation of UV detection sensitivity. In order to overcome this 
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limitation of UV detection, a sensitive LC-MS method was developed for measurement 
of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations 
in human plasma. [28] This method provided a ten-fold improvement on the detection 
sensitivity (5 ng/mL) compared to that of the most sensitive UV assay. In addition, a 
better specificity was also achieved by using mass spectrometry. A more sensitive and 
more specific HPLC-MSMS was also developed for simultaneous low concentration 
determination of gemcitabine and its metabolite in human urine. [29] 
1.3.2 Quantification of dFdCTP in White Blood Cells 
Since gemcitabine is a prodrug, it can be activated only after entering the cells. The 
activation is a multi-phosphoration process limited by dCK. The resultant nucleotides are 
gemcitabine monophosphate (dFdCMP), dFdCDP and dFdCTP. Among them, dFdCTP is 
the main active metabolite proposed to incorporate into DNA, resulting in inhibition of 
DNA synthesis and finally cell death. In addition, pre-clinical models have demonstrated 
a good correlation between intra-cellular dFdCTP accumulation and cytotoxic activity of 
gemcitabine. Thus, dFdCTP can be considered pharmacologically the most important 
metabolite of gemcitabine. [30, 31] 
Due to the importance of dFdCTP concentrations in interpreting pharmacodynamic 
effect, the quantification of intracellular dFdCTP content is crucial for gemcitabine 
clinical evaluation. In recent years, several analytical methods on determination of 
dFdCTP have been published including the latest one by using tandem mass 
spectrometry.[32-35] However, all of them are derived from a pioneer publication on 
analysis of 9-beta-D-arabinofuranosyladenine 5’-triphosphate levels in murine leukemia 
cells by high-pressure liquid chromatography as early as 1977. [36] 
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1.4 Pharmacokinetics of Gemcitabine 
1.4.1 Distribution, Metabolism and Excretion 
Due to its short half life, gemcitabine is usually administered by continuous infusion so 
as to reach the targeting blood concentration (10-15 µM). After i.v. infusion, gemcitabine 
is rapidly distributed into total body water with half life ranging from 2 to 42 minutes by 
using non-compartmental analysis. [18, 20] In modelling pharmacokinetic analysis, 
gemcitabine shows linear kinetics between doses of 53 to 1000 mg/m2. Gemcitabine 
shows biphasic elimination kinetics, with a t½ α and t½ β of 3.5 min and 8 min 
respectively. The drug can be rapidly deaminated by cytidine deaminase, likely in the 
liver and the kidney, to dFdU which exerts only minimal antitumor activity. Peak dFdU 
concentrations were observed 5-15 minutes after the end of gemcitabine infusion. [18] 
Unchanged parent drug accounts for only 5% of the dose and the rest of the gemcitabine 
dose is excreted as dFdU. Elimination of dFdU is biphasic with an initial t½ of 23.5-27 
minutes and a terminal t½ of 14-22.4 hours. About 98% of the gemcitabine dose is 
eliminated in the urine within one week. In addition, gemcitabine can be metabolized 
intracellularly by nucleoside kinases to active metabolites dFdCDP and dFdCTP; also 
metabolized intracellularly and extracellularly by cytidine deaminase to inactive 
metabolite difluorodeoxyuridine (dFdU). [37] The plasma protein binding is less than 10% 
due to its high polarity. [38] The proximal tubule of the kidney is known to be capable of 
nucleoside reabsorption. It is not clear if there are multiple different active nucleoside 
transporters. However, high concentrations of deaminase in kidney may contribute to the 
fast deactivation of gemcitabine to dFdU. [39] Gemcitabine Triphosphate in peripheral 
mononuclear cells appears to be saturated at a dosage of 350 mg/m2 through the 30-
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minute infusion of gemcitabine. This corresponds to the saturation of the rate-limiting 
enzyme deoxycytidine kinase in the cell. [18] In another study to determine if the 
saturation of dFdCTP was infusion rate dependent, a similar dose of 790 mg/m2 to 800 
mg/m2 with different infusion rates resulted in a 4-fold higher dFdCTP accumulation with 
a longer infusion time (60 min) than that with a shorter infusion time (30-minute) [40] 
 
1.4.2 Pharmacokinetic Parameters of Gemcitabine 
Gemcitabine shows linear kinetics between doses of 53 to 1000 mg/m2 and can be 
described by a 2-compartment model. The volume of distribution of gemcitabine is 
influenced by many factors such as infusion scheduling, age and sex. [41] This study 
showed that the volume of distribution is increased with longer infusions suggesting 
slowly equilibrating body compartments. However, clearance of gemcitabine is 
independent of the dose and the duration of infusion. But clearance of gemcitabine is 
quite variable with sex and age.  
A phase I study designed to evaluate the clinical feasibility of this pharmacologically-
based strategy showed that high weekly doses of gemcitabine administered at a fixed 
dose rate of 10 mg/m2/min was effective for patients with refractory malignancies with 
9.7% response rate and toxicity was tolerable. [42] The fixed infusion rate of 10 
mg/m2/min has been shown to achieve plasma gemcitabine concentrations of 15 to 20 
µM, resulting in maximizing the intracellular rate of accumulation of the active dFdCTP. 
Similar maximum concentrations (18.0 µM[43] and 18.6 µM[44]) were also achieved in 
other two clinical studies for fixed rate infusion of gemcitabine at 10 mg/m2/min for 80 
min or 120 min respectively. However, there were also some exceptional cases reported 
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such as a clinical trial conducted in The University of Texas MD Anderson Cancer 
Centre showed a nearly doubled Cmax (35.3 µM) [20] was achieved after the fixed rate 
infusion of gemcitabine at 10 mg/m2/min for 120 min (Table 1.1). 
 





























































































†: The value of AUC was calculated according to corresponding Clearance and Dose. 
1: University of North Carolina. [43]  
2. The University of Texas MD Anderson Cancer Centre. [18] 
3. Zhejiang University, China. [44] 
4. The University of Texas MD Anderson Cancer Centre. [20]  
5. City of Hope Comprehensive Cancer Center. [45] 
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1.5 Pharmacodynamics of Gemcitabine 
Gemcitabine displays potent anticancer effects on several cancers, especially for solid 
tumors. Hematological toxicity is the major adverse effect of gemcitabine even though 
this generally used anticancer agent has been thought to be tolerable in most cases. The 
mechanisms of action for gemcitabine have been explored intensively in last decade. Its 
main mechanisms of action and pharmacodynamics will be briefed as follows. 
 
1.5.1 Mechanism of Action 
Like other prodrugs, gemcitabine is also needed to be activated by dCK through 
intracellular phosphorylation for its anticancer activity. It enters the cell through the 
sodium-dependent nucleoside transporter on the cell membrane and then undergoes 
phosphorylation to the active dFdCDP and dFdCTP. (Figure 1.2) Both dFdCDP and 
dFdCTP inhibit processes required for DNA synthesis even though they target different 
sites. The main mechanisms include inhibition of DNA synthesis, ribonucleotide 
reductase inhibition, poisoning Topoisomerase I and self-potentiation. Preclinical and 
clinical data suggest that many factors such as enzymes, transporters and tumour type 
may affect the intracellular gemcitabine phosphorylation activation. [47] 
 
1.5.1.1 Reduction of DNA Synthesis 
Biochemical studies demonstrated that the ultimate intracellular fate of gemcitabine is to 
become incorporated into DNA, causing cell death. [47] DNA synthesis decreased in an 
inverse relationship with the cellular accumulation of gemcitabine nucleotides. [12] A 
strong correlation was found between incorporation of gemcitabine into DNA and the 
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loss of viability which provided evidence for a mechanistic relationship between the 
mechanism of gemcitabine and its biologic actions. Incorporation of dFdCTP into DNA 
chain is most likely the major mechanism by which gemcitabine causes cell death. After 
incorporation of gemcitabine nucleotide on the end of the elongating DNA strand, one 
more deoxynucleotide is added, resulting in inhibition of further DNA synthesis. DNA 
polymerase epsilon is unable to remove the gemcitabine nucleotide and repair the 
growing DNA strands which resulted in masked chain termination. 
 
1.5.1.2 Ribonucleotide Reductase Inhibition 
The ribonucleotide reductase is the major source of deoxynucleotides, which are 
necessary components for DNA replication and for repair. The effect of gemcitabine on 
ribonucleotide reductase activity is closely correlated to a decrease in the concentration of 
deoxynucleotides in cells shortly after being exposed to the drug.[13] This is because 
nucleotides of dFdC may be viewed as potential alternative substrates or inhibitors of 
ribonucleotide reductase, causing a decrease of deoxynucleotide pools. Surprisingly, the 
analogue of gemcitabine, cytarabine, lacks this effect due to minor difference in their 
chemical structure. Studies with partially purified human enzyme indicated that dFdCDP 
is the inhibitory metabolite. [48]  
 
1.5.1.3 Poisoning Topoisomerase I 
The effects of gemcitabine incorporation on topoisomerase I (top1) activity and the role 
of top1 poisoning in gemcitabine-induced cytotoxicity in cancer cells were tested by 
purified oligodeoxynucleotides. It was found that top1-mediated DNA cleavage was 
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enhanced when gemcitabine was incorporated immediately 3' from a top1 cleavage site 
on the nonscissile strand. This position-specific enhancement was attributable to an 
increased DNA cleavage by top1 and was likely to have resulted from a combination of 
gemcitabine-induced conformational and electrostatic effects. [49]  
 
1.5.1.4 Self-Potentiation 
Furthermore, the unique actions that gemcitabine metabolites exert on cellular regulatory 
processes serve to enhance the overall inhibitory activities on cell growth. This 
interaction is termed "self-potentiation" and is evidenced for very few other anticancer 
drugs. [50] The reduction in the intracellular concentration of natural dCTP pool by the 
action of gemcitabine diphosphate enhances the incorporation of gemcitabine 
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1.5.2 Molecular Pharmacology of Gemcitabine 
Cell-cycle kinetic studies have shown that gemcitabine is most active during the S phase. 
No obvious effect on the G1, G2, or M phases is seen. Due to the competitive inhibition, 
gemcitabine enters the cell through a saturable carrier-mediated process that is shared by 
other nucleosides. In addition, this process can even be reversible when normal 
nucleosides are increased continuously. Gemcitabine can be phosphorylated into its 
active metabolites once it enters the cell. These active metabolites vary significantly from 
patient to patient since the activation processes are controlled by a series of enzymes 
involved in its transportation, activation as well as elimination. In addition, the 
accumulation of gemcitabine di or triphosphates is also dependent on the infusion rate 
which is the rationale for proposing prolonged infusion of gemcitabine. [51] 
 
1.6 Pharmacogenetics of Gemcitabine 
Gemcitabine is used for several solid tumors including non-small cell lung cancer 
(NSCLC) but the determinants of toxicity and efficacy are not yet fully understood.   
 
1.6.1 Pathway of Disposition of Gemcitabine Metabolism 
The genetic metabolism pathway of gemcitabine to its active form gemcitabine 
triphosphate and gemcitabine diphosphate is complex (Figure 1.3). Gemcitabine enters 
the cell via members of the nucleoside transporter family, SLC28 and SLC29. [52, 53] 
Within the cell, gemcitabine is phosphorylated in a rate-limiting step by dCK to dFdCMP 
and subsequently by nucleotide kinases to dFdCDP and dFdCTP. Gemcitabine 
triphosphate is incorporated into DNA by DNA polymerase α and through the process of 
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masked chain termination inhibits DNA repair and synthesis. Gemcitabine and dFdCMP 
can be inactivated by CDA and deoxycytidylate deaminase (DCTD) to dFdU and 
difluorodeoxyuridine monophosphate (dFdUMP), respectively. [12] Additional targets of 
gemcitabine cytotoxicity are ribonucleotide reductase (RRM1, RRM2) and thymidylate 
synthase (TYMS) which are inhibited by dFdCDP and dFdUMP respectively. RRM1 
converts ribonucleotides to deoxyribonucleotides which are used in DNA synthesis and 
repair. [48] The inhibition of TYMS results in DNA damage. 
 
 
 Figure 1.3 Metabolism pathway of gemcitabine to its active metabolites     
 dFdCDP and dFdCTP. 
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1.6.2 Identification and distribution of SNP 
Inherited genetic variation in drug metabolizing enzymes, targets and transporters are 
associated with inter-patient and inter-ethnic variability in drug effect.  Genetic variations 
may be due to mutations, variation in tandem repeats and single nucleotide 
polymorphisms (SNPs), which account for over 90% of genetic variation in the human 
genome.[54, 55] Evaluating the association between gene variants involved in the 
gemcitabine pathway and clinical outcome is able to elucidate the effect of gene 
polymorphisms on chemotherapeutic outcome. 
 
1.7 Toxicity of Gemcitabine 
The profiles of the general pharmacological effects of gemcitabine were assessed in 
studies evaluating the cardiovascular and respiratory systems, renal function, the 
gastrointestinal system, the central nervous system, and the autonomic nervous system 
using animal models.[56] In general, gemcitabine showed limited organ toxicity but 
unpredictable severe toxicity such as myelosuppression. 
 
1.7.1 Non-hematology Toxicity 
Non-hematologic toxicity comprises fever, chills rigors, hypotension, flu-like symptoms, 
rash, alopecia, nausea, vomiting, constipation, diarrhea, stomatitis, somnolence, lethargy 
insomnia, elevated liver enzymes, proteinuria, hematuria, elevated creatinine and 
dyspnea. Hemolytic uremic syndrome has been reported in several cases. Among these, 
flu-like symptoms are common but can be relieved by acetaminophen. These results 
indicated that gemcitabine has a low potential to produce severe adverse pharmacological 
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effects on organs except for lungs. [57] 
 
1.7.2 Hematology Toxicity 
Like that of other antimetabolites, the dose-limiting toxicity of gemcitabine is 
myelosuppression. Myelosuppression consists of neutropenia, thrombocytopenia and 
anemia. The frequency of WHO Grade 3-4 adverse effects was summarized by Hui and 
Reitz. [1] The frequency ranges are 6-51%, 1-14% and 0.2-51% for neutropenia, anemia 
and thrombocytopenia respectively. These high variations in neutropenia and 
thrombocytopenia represent a major challenge in management of hematological toxicities 
during gemcitabine-based chemotherapy. The reasons could be due to different doses, 
different diseases, and different concurrent therapy as well as different genetic profiles, 
e.g. mutation of cytidine deaminase. [58]  
 
1.7.3 Models for Gemcitabine-induced Neutropenia  
Modelling the relationship between dose and concentration of anticancer drugs with 
myelosuppression is very important for clinicians to understand interpatient variability 
and select a better individualized treatment. This is because the use of these drugs is often 
limited by myelosuppression toxicities. This work can be done by empirical or 
physiology-based models. The most commonly used pharmacokinetic parameters are 
peak plasma concentration, the area under the concentration-time curve (AUC), time 
above certain plasma drug concentration and concentration at steady state (for continuous 
infusion). [59] For high protein bound compounds, the free drug concentrations would be 
calculated in evaluating their activities. Empirical neutropenic models have been 
Chapter I: Literature Review 
 18
established for many drugs such as tipifarnib, irinotecan, etoposide and epirubicin, etc. 
[60-63] Comparatively, physiology-based models are preferred because ideal physiology-
based models are able to separate system parameters, common across drugs, from drug 
specific parameters. [64-66] However, these modeling procedures are time consuming and 
well trained modelers are required to build and optimize the pharmacokinetic and 
pharmacodynamic models.  
 
1.8 Preclinical Research of Gemcitabine 
1.8.1 in vitro Studies 
Nucleoside antimetabolites comprise one of the most effective classes of drugs for the 
treatment of cancer and viral diseases. Usually, nucleoside analogues are prodrugs and 
display their activities only after entry into the cell and phosphorylation to nucleotide 
metabolites. Gemcitabine has been confirmed to exhibit activity on several solid tumors 
due to its unique multiple mechanisms of action. Gemcitabine is regarded as a new 
landmark drug of antimetabolites in the past decade.  
Preclinical studies revealed gemcitabine had potent and broad spectrum activity against a 
variety of hematological and solid tumour cell lines like colorectal, renal cell, melanoma 
and NSCLC cells, etc. The antitumour activity against human myeloid HL-60, T-
lymphoid Molt-3, B-lymphoid RPMI-8392 cell lines was 2.6 to 17.3 fold higher than 
cytarabine after 48 hour incubation. [67-68] 
Concurrent addition of deoxycytidine to the cell culture system may cause about a 1000-
fold decrease in its biological activity. This implies that the activity of gemcitabine can be 
competitively inhibited by saturating dCK. [69] 
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1.8.2 In vivo Studies 
In human tumor xenografts derived from squamous cell carcinoma of the head and neck, 
gemcitabine was active.[70] Gemcitabine was tested for its antitumor effect in human 
tumor xenografts derived from squamous cell carcinoma of the head and neck (SCCHN). 
At equitoxic doses, gemcitabine was more active in this model than the drugs that are 
clinically used in SCCHN, i.e., cisplatin, methotrexate, 5-fluorouracil, and 
cyclophosphamide. 
A mode of resistance appeared to be lack of the activating enzyme dCK. Gemcitabine is 
not affected by the P-glycoprotein. [71] In an in vivo induction of gemcitabine resistance 
mode, an increase in expression of the RRM1 subunit gene was found in resistance 
phenotype but dCK activity was 1.7-fold decreased. [72] Preclinical studies demonstrated 
treatment schedule dependency of gemcitabine. The data on the effect of gemcitabine in 
animal tumour models indicated that the time interval between i.v. push injections was 
important when intermittent schedules were used and continuous infusions over a 24-
hour period might be highly effective for in vivo models.[73] It was found that treatment 
with 120 mg/kg gemcitabine, injected (i.p.) four times at 3-day intervals, was more 
effective than the schedules of daily (five times 2.5 to 3.5 mg/kg) or weekly (two times 
240 mg/kg) injections.  
In addition, the lack of cross resistance seen with gemcitabine may contribute to 
therapeutic synergism when gemcitabine is combined with other agents [74] In general, in 
vitro sensitivity to dFdC was highly related with dFdCTP accumulation and retention, but 
in vivo this relation was less clear. [75] Furthermore, the effect of gemcitabine is also 
dependent on dose scheduling.  Previous mechanistic studies indicate that a continuous-
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infusion schedule may be more effective compared to bolus injection. Furthermore, 
prolonged infusion of gemcitabine can give better antitumor activity and shows promise 
of being active in clinical trials. [21]  
 
1.9 Clinical Uses of Gemcitabine 
Despite the grim prognosis of NSCLC, some progress has been made in defining the role 
of chemotherapy in this once considered chemo-resistant disease. In the 1970s and 1980s, 
a number of chemotherapeutic agents were tested in phase II trials, of which several of 
them fulfilled the criteria of 15% overall response rate, considered to be “active” enough 
for further evaluation. These include cisplatin, ifosfamide, mitomycin-C, vinblastine, 
vindesine, and etoposide. [76] Accordingly, a series of combination clinical trials being 
proposed and tested in Europe and US resulted in superior cisplatin-based combination 
chemotherapy as a standard treatment of NSCLC. To date, platinum-based combinations 
are the most widely accepted regimens in the treatment of advanced NSCLC due to a 
clear improvement on survival in comparison with best supportive care alone.[77] Since 
the response rates have nearly reached a plateau for the cisplatin combination 
chemotherapies for NSCLC, novel doublets are continuously being explored by clinician 
scientists to provide improved treatment efficacy, less toxicities and better quality of life. 
This has been achieved with the development of third generation of agents which have 
been active for NSCLC. These agents include taxanes (paclitaxel and docetaxel), 
gemcitabine, vinorelbine, and irinotecan.[78] The candidate drugs used for combination 
therapy should possess proven anticancer effect, as well as tolerable toxicities. Among 
these new anticancer drugs, gemcitabine has been considered a potential agent for 
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combination chemotherapy due to its unique mechanism of action and relatively “good” 
toxicity profile.[14]  
 
1.9.1 Single-agent Gemcitabine 
Both in vitro and in vivo studies have demonstrated that gemcitabine is effective on 
various solid tumours, including NSCLC. [10] Used as a single agent in the treatment of 
metastatic NSCLC, gemcitabine achieved consistent response rates of 20% and above. 
Furthermore, the toxicity profile at the doses ranging from 800 to 1250 mg/m2 was 
modest, consisting mainly of a short-lasting decrease in leucocytes and thrombocytes, 
skin reactions (5-8%), peripheral oedema and transient increase in transaminase levels.[79] 
Nausea and vomiting were mild. Some patients (18.9%) experienced transient flu-like 
symptoms and mild fever was reported in 37.3% of flu patients. [80] Based on its response 
rates and modest toxicity which is non-overlapping with other active agents, gemcitabine 
is now being widely explored in various combination therapies in the treatment of 
NSCLC.  
 
1.9.2 Gemcitabine plus Platinium Compounds 
In vitro studies showed considerable synergy between cisplatin and gemcitabine.[81] 
Clinically, gemcitabine/cisplatin combination also showed an improved median and one 
year survival rate compared to single cisplatin, better time-to-disease progression and 
tumour response rates than its comparator arms in phase III studies. [82, 83]  These 
significant findings reviewed by FDA resulted in the approval of gemcitabine in 
combination with cisplatin as first-line therapy of patients with advanced NSCLC 
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patients. The efficacy of the every 4 week regimens was further confirmed by other 
investigators in the following trials. [84-86] In recent years, a more common schedule is 
every 3 weeks for gemcitabine 1000 or 1250 mg/m2 given on day 1 and 8 combined with 
cisplatin at doses ranging from 75 to 100 mg/m2. [87-89] These every three weeks schedule 
studies achieved equivalent response rates that ranged from 31.8%-42% as the every four 
weeks schedule with a response rates between 25.9% and 54.8% but with less 
myelotoxicity and better compliance. [90-94]This could be due to the difference in the dose 
intensity of each schedule of gemcitabine. 
Although the gemcitabine and cisplatin combination is currently one of the reference 
regimens for advanced NSCLC, this regimen has its own limitation due to significant 
non-hematologic toxicity and difficulty of use in outpatients (the need for hydration and 
prolonged administration time). In contrast, carboplatin, another platinum analogue, has 
less non-hematological toxicity associated with cisplatin. The efficacy of gemcitabine and 
carboplatin combination was confirmed by a recent Phase III trial to compare overall 
survival in patients with locally advanced or metastatic NSCLC when treated with single-
agent gemcitabine versus gemcitabine/carboplatin. [95] In advanced NSCLC, 
gemcitabine/carboplatin therapy resulted in significant survival benefit compared with 
single-agent gemcitabine.  
In addition, the gemcitabine and carboplatin doublet is effective, with a favorable safety 
profile, and is well tolerated in the outpatient setting. Even though gemcitabine combined 
with carboplatin is associated with more hematological toxicity, but the incidence of non-
hematological toxicity is significantly lower. Another advantage is that carboplatin can be 
easily administered in an outpatient setting since no prehydration is needed. [96] 
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1.9.3 Gemcitabine plus non-platinium agents 
Since 1997, platinum-based combination has been recommended by ASCO for treatment 
of advanced NSCLC. Until 2003, a new guideline has been updated as “A First-line 
chemotherapy given to patients with advanced NSCLC should be a two-drug combination 
regimen. Non–platinum-containing chemotherapy regimens may be used as alternatives 
to platinum-based regimens in the first line”. [97] In recent years, a variety of 
gemcitabine-based combinations with non-platinum agents have been investigated for 
their efficacy, toxicity as well as quality of life. The efficacies of gemcitabine-based 
doublets combined with docetaxel, paclitaxel, or vinorelbine compared to any platinum-
based doublets or the single-agent schedules have been well documented in several Phase 
II trials [98-101] and further confirmed by Phase III studies as well. [102-105]  
 
1.10 Nucleoside Transporters 
Gemcitabine can be activated to its active metabolites only after entering the cell. Like 
other nucleoside drugs, gemcitabine is hydrophilic and would not be expected to readily 
permeate the plasma membrane by passive diffusion. Cellular uptake of gemcitabine 
requires the presence of specialized plasma membrane nucleoside transporter proteins. 
[106] Gemcitabine has been shown to be a substrate for five of the nucleoside transporters 
found in human. These transporters belong to the Solute Carrier families SLC28 (human 
concentrative nucleoside transporters: hCNT1, hCNT2 and hCNT3) and SLC29 (human 
equilibrative nucleoside transporters: hENT1 and hENT2). [107] CNTs are thought to play 
critical roles in nucleoside homeostasis at the organism level by maintaining systemic 
blood levels of nucleosides through absorption and elimination mechanisms and at the 
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cellular level by mediating influx of extracellular nucleosides into cells. On the other 
hand, these transporters play a critical role in drug response, facilitating drug absorption, 
metabolism, and elimination. Hence, genetic mutation in SLC transporters could be 
determinants of sensitivity and resistance to gemcitabine and toxicity of gemcitabine. 
 
1.10.1 Effect of Nucleoside Transporters on Activity of Gemcitabine 
Gemcitabine requires plasma membrane nucleoside transporter proteins to efficiently 
enter cells and exert its cytotoxicity. In vitro studies have demonstrated that deficiency of 
human equilibrative nucleoside transporter 1 (hENT1), the most widely abundant and 
distributed nucleoside transporter in human cells, confers resistance to gemcitabine 
toxicity. Patients with pancreatic adenocarcinoma with uniformly detectable hENT1 
immunostaining have a significantly longer survival after gemcitabine chemotherapy than 
tumors without detectable hENT1. Immunohistochemistry for hENT1 shows promise as a 
molecular predictive assay to appropriately select patients for palliative gemcitabine 
chemotherapy but requires formal validation in prospective, randomized trials. [108]   
 
1.10.2 Effect of Nucleoside Transporters on Excretion of Gemcitabine  
Eliminatory organs such as kidney, liver, and intestine defend the human body against 
potentially harmful effects of xenobiotics by transforming them into less active/inactive 
metabolites and by excretory transport process. Eventually, most drugs and 
environmental toxicants are excreted into the urine, either in the unchanged form or as 
biotransformation products. The mechanisms that contribute to their renal excretion are 
closely related to the physiological events occurring in the nephrons, i.e., filtration, active 
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secretion, and re-absorption.[109] The SLC28 family consists of three subtypes of sodium-
dependent, concentrative nucleoside transporters, CNT1, CNT2, and CNT3 (SLC28A1, 
SLC28A2 and SLC28A3, respectively). Each of them has their own substrate 
specificities. CNT1 is pyrimidine-nucleoside preferring, CNT2 is purine-nucleoside 
preferring but CNT3 has a more general substrate profile and can transport pyrimidine 
and purine nuclosides as well. [110] Novel evidence indicates that cytidine is a novel 
substrate for wild-type CNT2. [111] Both CNT1 and CNT2 are involved in re-absorption of 
nucleosides.  
In epithelia, CNT1 is localized to the apical membrane and works in concert with 
equilibrative nucleoside transporters localized predominately to the basolateral 
membranes of these tissues to mediate transepithelial nucleoside flux. Although CNT1 
prefers pyrimidine nucleoside, it works on transportation of naturally occurring 
pyrimidine nucleosides as well as the naturally occurring purine nucleoside, adenosine. 
[112,113] Many antiviral nucleoside analogues and cytotoxic cytidine analogues including 
gemcitabine are substrates of CNT1.  
Northern blot analysis has confirmed that human CNT2 is present in many tissues such as 
kidney, liver and heart, etc. [114] CNT2 shows different profile of substrates including 
antiviral compounds such as didanosine in treatment of HIV and ribavirin in treatment of 
hepatitis C. Of the nucleoside chemotherapeutic agents, it seems that these compounds 
are not the substrates of CNT2. However, a recent study demonstrated that gemcitabine is 
one of the substrates of CNT2. [115] Although each subtype of CNTs shows different 
substrate specificities, their specificities may become different due to transporter protein 
conformation changes. For example, the specificity of substrate for CNT1 can be 
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broadened from pyrimidine to pyrimidine plus purine nucleosides after replacing Ser318 
in rat CNT1 with corresponding residue in CNT2 (Gly). This fact implies that the single 
nucleotide polymorphism which encodes amino acid changes is important in determining 
the substrate profile for CNTs. This may produce significant clinical implication in 
interpreting efficacy and toxicity of nucleoside anticancer drugs. 
 
1.11 Chemo-resistance of Gemcitabine 
Like other chemotherapeutic agents, treatment effect of gemcitabine is also limited in 
clinical trials as a single agent or combination regimens due to resistance to gemcitabine. 
This resistance is believed to be caused by different activity and mutation of several 
enzymes which control the phosphorylation of gemcitabine and intracellular 
transportation as well as elimination processes. These include 1) human equilibrative 
transporter (hENT1); [116] 2) multidrug resistance proteins ABCC1 and ABCC5; [117] 3) 
gemcitabine intracellular phosphorylation by deoxycytidine kinase (dCK) to the active di 
or triphophate forms; [13] 4) Overexpression of rebonucleotide reductase (RRM1); [118] 5) 
Decreasing the intracellular normal deoxynucleotide triphosphate pools by inhibition of 
ribonucleotide reductase. [119] On the other hand, the sensitivity to gemcitabine also 
depends on the NSCLC pathological characteristics in relation to mutation and deficiency 
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1.12 Summary 
Lung cancer is the most common form of cancers throughout the world. In addition, 
advanced NSCLC is usually considered incurable. The development of third generation 
anti-cancer drugs such as taxanes, irinotecan and gemcitabine brings new hope in the 
armamentarium of drugs for chemotherapy for NSCLC. For the last ten years, the 
combination of platinum-based chemotherapy has resulted in significant improvements in 
treatment of NSCLC patients. Nevertheless, another treatment plateau (response rates of 
30-40%, median survival times of 8-10 months and 1-year survival rates of 
approximately 35% in patients with advanced NSCLC) has been reached even with the 
use of the third generation agents. [120]Although gemcitabine has been used in solid 
tumour treatment for more than ten years, there is still room to improve its efficacy by 
manipulating different infusion rates and dosages with the help of clinical 
pharmacologically-guided research. These findings will help clinicians to maximize the 
efficacy of gemcitabine and at the same time, manage the drug toxicity effectively 
through optimizing pharmacokinetic parameters and tailoring pharmacogenetics findings 
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Our study aims are: 
1. in vitro studies on cytotoxic sensitivities of NPC and NSCLC cell lines to 
gemcitabine and delineating the determinants for intracellular accumulation and 
retention of dFdCTP. 
 
2. Pharmacokinetic and pharmacodynamic study in fixed infusion rate of different 
dose of gemcitabine in combination with carboplatin (Phase I).  
 
3. Pharmacokinetic and pharmacodynamic study of gemcitabine in 2 different 
infusion rates of gemcitabine with carboplatin in patients with advanced NSCLC 
(Phase II).  
 
4. Association of pharmacokinetic parameters of gemcitabine in plasma or the 
intracellular dFdCTP with the various pharmacodynamic endpoints and 























Bioanalytical Method Development for 
Determination of Gemcitabine  











2.1.1. Quantification of dFdC and dFdU in human plasma using LC-MSMS 
Gemcitabine plasma concentrations have been reported to be closely related to rate of 
accumulation of its intracellular therapeutically active metabolite-gemcitabine 
triphosphate even though gemcitabine is a prodrug,[14] Plasma quantitation of dFdC is 
difficult because it has an extremely short half-life due to rapid deamination to dFdU by 
CDA. [53,121] In addition, simultaneous analysis of dFdC and dFdU is important to define 
the elimination pathway of parent drug and its metabolites. [16] Furthermore, the ratio of 
AUC or concentration ratios of dFdU versus dFdC may be useful for evaluating 
gemcitabine deactivation rate which may be an important marker for drug efficacy. [122] 
During our phase I clinical study of gemcitabine, a HPLC-UV method was validated for 
quantification of gemcitabine and dFdU with the lower limit of quantitation (LLOQ) of 
80 ng/ml. [123] However, most of the concentrations from the last sampling points from 
our Phase II trial study are less than 80 ng/mL. Hence accurate determination of the last 
sampling points of dFdC during the elimination phase was not possible by using UV 
detectors because of, the rapid decline of dFdC plasma concentration after the end of 
infusion and the limitation of UV detection sensitivity. This gap in sensitivity of 
measurements initiated the development of the current much more sensitive and simpler 
analytical method using liquid chromatography-tandem mass spectrometry.  
In the clinical setting, gemcitabine's unique mechanism of action and its lack of 
overlapping toxicity with other cytotoxic agents make it as an ideal candidate for 
combination therapy. [23] Many novel gemcitabine combinations are being tested in 
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clinical trials resulting in a large number of plasma samples requiring quantitative 
analysis. Although two mass spectrometric assays were published for determination of 
dFdC and dFdU in human plasma and urine, [28, 29] the solid phase extraction (SPE) used 
for sample preparation is laborious and precludes rapid quantifications of dFdC and dFdU 
in patient plasma samples, especially in clinical laboratories. This is likely to hamper the 
widespread application of monitoring dFdC and dFdU concentrations in clinical practice 
due to shortage of trained analytical scientists. In addition, an analogue compound of 
gemcitabine was used as internal standard which may result in bias pharmacokinetic 
parameters due to matrix effect. Furthermore, the volume of plasma required for bio-
analysis is an important consideration in pharmacokinetic sampling, especially for 
pediatric clinical trials. In the LC-MS assay for plasma samples, 500 µl was used in 
quantification of dFdC and dFdU. [28] This sample volume is ten time larger than what we 
used (50 µl) in current LC-MSMS method. Due to the large difference in polarities of 
dFdC and dFdU (Figure 2.1), a gradient elution mode must still be utilized to 
simultaneously quantify both dFdC and dFdU even though tandem MS is a highly 
selective detector. The key limitation against high-throughput analyses of plasma samples 
is dependent on the sample preparation.  
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         Figure 2.1 The chemical structures of dFdC, dFdU and Internal Standard. 
 
 
In this study, we developed and validated a highly sensitive and simple liquid 
chromatography tandem mass spectrometry (LC-MSMS) method for dFdC and dFdU. 
Sample preparation involved only protein precipitation with acetonitrile, paving the way 
for high-throughput analysis of clinical samples. In addition, a commercially available 
isotope gemcitabine was used as internal standard. This ideal internal standard will allow 
analytical scientists to minimize the possible matrix effects. Therefore, this robust method 
is most applicable for clinical investigation of the pharmacokinetics of dFdC during 
elimination phase, to evaluate the AUC ratio of dFdC and dFdU as well as to monitor 
many samples within a short period. This method has been successfully applied to 
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2.1.2. Ion-exchange HPLC determination of dFdCTP in human WBC 
As a prodrug, gemcitabine has to go through intracellular conversion to its active 
metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Current research 
findings showed that dFdCTP is the main active metabolite and exerts its anticancer 
effect by incorporation into DNA chain. Several studies have confirmed that in vitro and 
in vivo efficacies as well as toxicity of gemcitabine are closely correlated to the 
intracellular accumulation of dFdCTP. Therefore, a sensitive and accurate analytical 
method is critical for clinicians to optimize the treatment schedule and correlate the 
intracellular pharmacokinetics of dFdCTP with pharmacogenetics, pharmacodynamics as 
well as cytotoxicity. However, bioanalytical method development is a challenge for 
quantifying intracellular active metabolite, dFdCTP because of 1) the large volume of 
blood needed for isolating enough white blood cells; 2) tedious procedure on handling, 
isolating white blood cells and cell counting; 3) sample stability during storage; 4) 
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2.2. Objectives 
The aims are to develop and validate a highly sensitive method for plasma dFdC and 
dFdU quantitation using LC-MSMS and to accurately quantify intracellular metabolite 
(dFdCTP) using ion-exchange HPLC coupled with UV detector to study 
pharmacokinetics of gemcitabine.  
 
2.3. Materials and Methods  
2.3.1. Reagents and Standards 
Gemcitabine hydrochloride (dFdC, LY 188011), Gemcitabine Triphosphate (dFdCTP, LY 
264368) and 2’, 2’-difluorodeoxyuridine (dFdU, LY 198791) were kindly provided by Eli 
Lilly. (Indianapolis, IN, USA). The internal standard, Gemcitabine-13C, 5N2 
Hydrochloride, was purchased from Toronto Research Chemicals, Inc. (North York, ON, 
Canada). Tetrahydrouridine (THU) was purchased from Biosciences, Inc. (La Jolla, CA, 
USA). Ammonium dihydrogen phosphate (AG), phosphoric acid (AG), HPLC grade 
methanol and acetonitrile were purchased from Merck (Darmstadt, Germany). Milli Q 
water was used for mobile phase preparation. 
 
2.3.2. Sample Collection and Pretreatment  
This clinical trial was approved by the institutional review board of National Health 
Group of Singapore. Blood samples were collected from patients before initiation 
baseline (0 min) of a 30- to 75-minute gemcitabine infusion, 10 minutes, 30 minutes 
during infusion, 10 minutes before the end of the infusion, and 30 minutes, 1 hour, 2 
hours after the end of the infusion. At each point, 8 ml of blood was drawn into 15-ml 
Chapter II:BIOANALYTICAL METHOD DEVELOPMENT 
 35
heparined plastic tubes that had been preloaded with 0.1 ml of a 10 mg/ml solution of 
tetrahydrouridine, a cytidine deaminase inhibitor. Blood samples were centrifuged for 15 
minutes at approximately 1,200 ×g at room temperature. The plasma portion of the 
samples were removed and kept at –20 °C until analysis. The buffy coat was for 
mononuclear blood cell isolation for quantification of dFdCTP, the intracellular main 
active metabolite.  
 
2.3.2.1. Plasma Sample Preparation 
Fifty microlitre of plasma or calibrator sample, 5 μl of 50 μg/ml aqueous solution of 
Gemcitabine-13C, 5N2 (internal standard), and 200 μl of acetonitrile were added together 
in a 1.5 ml Eppendorf tube. The tube was tightly capped and immediately vortex-mixed 
for 1 minute, and then centrifuged at 10,000×g for six minutes at 4 °C. One hundred 
microlitre of supernatant was transferred into another Eppendorf tube and dried under 
nitrogen and reconstituted with 50 μl of 10 mM ammonia acetate buffer solution pH 6.8. 
After mixing, 40 μl of the mixture was transferred to plastic insert for LC-MSMS 
analysis.  
 
2.3.2.2. Blood Cell Preparation 
2.3.2.2.1. WBC Isolation 
The buffy coat (1 ml) was gently collected using Pasteur pipette and transferred into a 15 
ml centrifuge tube. Balanced salt solution was added to make the volume of cell 
suspension to be 6 ml which is equal to the original blood volume used. The cell 
suspension was mixed using Pasteur pipette. Three milliliter of Ficoll-Paque was added 
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to another centrifuge tube (2 tubes for each point). Three milliliters of the diluted blood 
was layered carefully over the Ficoll-Paque. Next, the tubes were capped and centrifuged 
at 250 ×g at 5 °C for 20 minutes. The upper layer was drawn off carefully while leaving 
the WBC layer undisturbed. The WBC layer was collected and diluted with saline to 3 
ml. Twenty microlitres of cell suspension were diluted with 80 µl of 3% acetic solution 
and counted with hemacytometer. The number of WBC was calculated as follows: 
 N WBC = 5 (dilution factor) × cell number within each square × 104 (cells/ml). 
 
 
2.3.2.2.2. Storage of Cell Samples 
The remaining isolated WBC except those (20 µl) for counting was centrifuged at 500 ×g 
at 5 °C for 6 min. The supernatant was decanted off gently and the tube was put upside 
down on the tissue paper to drain off the water in the tube wall. The tubes were immersed 
in liquid N2 and kept in -80 ºC.  
 
2.3.2.2.3. Pre-analytical Preparation of WBC Samples 
Eighty microlitres of HClO4 (0.8 M) was added to the tube containing the WBC pellets 
above, vortex-mixed for 30 seconds and kept on ice for 3 min. Then the tube was 
centrifuged at 10,000 g at 4 ºC for 2 min. The supernatant was transferred to another 
centrifuge tube (0.6 ml) and the volume was adjusted to 130 µl. After that, 70 µl of 0.8 M 
KOH was added and the tube was kept on ice for ten min and centrifuged at 10,000 ×g at 
4 ºC for 5 min. The supernatant (150 µl) was transferred into injection insert tube (200 
µl) and 100 µl was injected into HPLC system for analysis. 
 
Chapter II:BIOANALYTICAL METHOD DEVELOPMENT 
 37
2.3.3. Instrumentation 
2.3.3.1. HPLC-MSMS (dFdC and dFdU) 
The high-performance liquid chromatographic system was comprised of an Agilent 1100 
Binary pump equipped with an Agilent 1100 autosampler injector with 100 µl loop and 
1100 column oven set at 20°C (Germany). Chromatographic separations were achieved 
using a BDS HYPERSIL C18 column (2.1×100 mm) (Thermo Hypersil-Keystone, USA) 
following an Eclipse XDB-C8 guard column (2.1 mm x 50 mm, 5 µm) (Agilent 
Technologies, USA) with gradient elution of the analytes with an initial mobile phase 
composition of 2% methanol in 10 mM ammonium acetate buffer pH 6.8 (2:98, v/v). 
Methanol was increased to 15% in 1 min maintained for 4 min and decreased back to 2% 
methanol again in 0.5 min. Column was equilibrated at 2% methanol for another 6.5 min 
before the next injection. The flow rate was set at 0.2 ml /min. Ten microliters of 
reconstituted supernatant were injected to the HPLC column and the elutant directed to 
the mass spectrometer turboionspray source without splitting. In order to avoid 
contaminating the ion source detector, the solvent front eluting in the first 2.5 min was 
switched to waste container.  
LC-MSMS analyses were performed using an API 2000 triple-quadrupole mass 
spectrometer (Applied Biosystems, MDS SCIEX, Ontario, Canada). The instrument was 
operated in positive ion mode calibrated by polypropylene glycol. The plasma samples 
were analyzed by tandem MS using the IonSpray needle at +5500 V and the cluster 
breaking orifice voltage at 30 V. The ions of dFdC at m/z 264, dFdU at m/z 265.1 and 
internal standard at m/z 267.0 were passed through the first quadropole (Q1) and the 
product ions for dFdC (m/z 112.1), dFdU (m/z 113.2) and internal standard (m/z 115.0) 
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were monitored through the third quadrupole (Q3). The dwell time per channel was 300 
ms for data collection. Analyst software (version 1.3) was used to process quantitative 
data analysis.  
 
2.3.3.2. HPLC-UV (intracellular dFdCTP) 
The high-performance liquid chromatographic system consisted of a Hewlett Packard 
(HP) 1050 quaternary pump equipped with a (HP) 1050 autosampler injector with a 100 
μl loop, HP 1100 variable wavelength UV detector and HP ChemStation for data 
analysis. The analytical column Column is partisphere 5 SAX (Whatman).  
The mobile phase was optimized through different buffers, pH values and gradient 
compositions as well. The optimized analysis conditions were listed as follows: 
• HPLC conditions: 
-HPLC column is partisphere 5 SAX (Whatman). 
--Mobile phase consists of solution 1 (0.5M Ammoniun dihydrogen phosphate 
buffer, pH was adjusted to 3.5 using 85% H3PO4) and Solution 2 (0.2 M, H3PO4 pH 
2.1). The gradient was listed as follows: 
Time:            Pump C              Pump D 
0’                45%               55% 
30’               75%               25% 
 31’               45%               55%  
 
• Flow rate was 1.5 ml/min and Detection wave length was 275 nm. 
• Retention time was 14.5 min for dFdCTP and 17.0 min for ATP. 
 
2.3.4. Standard Solutions and Calibration Curves 
2.3.4.1. Gemcitabine and dFdU 
Standard stock solutions of dFdC, dFdU and IS prepared in methanol at 1 mg/ml and 
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were kept at –20 °C. These stock solutions were diluted with water to obtain the 
concentrations required for preparation of standard working solutions. For dFdC, working 
solutions of 0.05, 0.1, 0.25, 1, 2.5, 5, 10, 20 μg/ml and for dFdU, working solutions of 
0.5, 1, 5, 10, 25, 50, 100 and 200 μg/ml were prepared. A working solution of internal 
standard was prepared at 5 μg/ml (Table 2.1). 
 
Table 2.1 Calibrator Preparation 
calibrators C1 C2 C3 C4 C5 C6 C7 C8 
IS (5 ug/ml) 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 
0.05 0.1 0.25 1 2.5 5 10 20 dFdC (µg/ml) 
Vol (µl) 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 
0.5 1 5 10 25 50 100 200 dFdU (µg/ml) 
Vol (µl) 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl 
Control plasma 
(THU, 0.2 g/10ml) 
50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 50 µl 
 
Least-squares regression and standard curves weighted according to 1/x (x = 
concentration) were drawn using linear regression of the peak area ratios of dFdC or 
dFdU against internal standard obtained from LC-MSMS analysis of standard solution 
against actual standard concentrations.  
The limit of detection (LOD) was defined as the lowest concentration that the analytical 
assay can reliably differentiate from background levels (S/N > 3). The lower limit of 
quantification (LLOQ) was defined as the lowest calibrator with the inter-day coefficient 
of variation < 20%. [124] 
2.3.4.2. Gemcitabine Triphosphate (dFdCTP) 
Intracellular dFdCTP determination was developed using external method. A series of 
calibrators were prepared using HONE 1 cell line as a surrogate for control white blood 
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cells. The HONE 1 cell pellet was treated the same way as white blood cell preparation. 
1000 µM of dFdCTP was prepared as stock solution and was stored at -20 °C. This stock 
solution of dFdCTP were spiked into the alkalined cellular supernatant to prepare a series 
of working solution with concentration values of  0.4, 1, 1.5, 2, 3, 4, 5, 10 µM. 100 µl of 
working solutions were injected into HPLC to produce a standard curve. QC samples 
were prepared as 1.2, 2.5, 7.5 µM. The accuracy and precision were evaluated using four 
samples at each concentration intra-run and inter-run. Stability of neutralized samples and 
reproducibility of method will be evaluated to guarantee robustness of analytical 
intracellular method.  
 
2.3.5. Validation Description 
2.3.5.1. Gemcitabine and dFdU in plasma 
Quantification was based on the ratios of the peak areas of dFdC and dFdU against that of 
internal standard. Validation was performed through establishing intra and inter-day 
accuracy and precision of the method on quality control samples. Five different 
calibration curves of seven calibrators of dFdC and dFdU were prepared to determine the 
quality control (QC) samples. To determine intra-day and inter-day precision and 
accuracy of dFdC and dFdU, the method presented here was validated by analyzing three 
quality control samples, prepared at the nominal concentrations of 15, 200, 800 ng/ml for 
dFdC and those of 150, 2000 and 8000 ng/ml for dFdU in blank human plasma. Intra-day 
variability was tested on five different human plasma QC samples using the same 
calibration curve. Inter-day variability was tested on five different days using calibration 
curves obtained daily. The precision of the method at each QC concentration was 
expressed as a coefficient of variation (%C.V.) by calculating the standard deviation as a 
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percentage of the mean calculated concentration, while the accuracy of the assay was 
determined by expressing the percentage of the mean from the true value.  
The absolute recoveries at three different plasma concentrations of dFdC (15, 200, 800 
ng/ml) and dFdU (150, 2000, 8000 ng/ml) in triplicate and internal standard at 5000 
ng/ml were determined by comparing the peak area of dFdC, dFdU or internal standard 
from samples obtained through complete sample preparation with those obtained from 
direct injection of equivalent pure substances spiked into post extracted blank plasma. . 
 
2.3.5.2. Matrix effect evaluation 
Matrix effect is a common and harmful phenomenon in LC-MS or LC-MSMS procedure. 
According to FDA bioanalytical method validation guidance for industry, matrix effect 
should be investigated to achieve good precision and accuracy. The matrix effect 
[ME(%)] was evaluated according to the following formula: [125] 
 
ME (%) = [Peak Area in control matrix/ Peak Area in neat standard]×100 … (1) 
 
In our current validation procedure, six patient control plasma samples were used for 
matrix effect evaluation and recovery for three compounds. The standard concentration 
levels were QC1 and QC3 for dFdC and dFdU and that for internal standard was 500 
ng/ml. Three sets of these two concentrations (QC1 and QC3) were prepared. The first set 
of two QCs (set A) was prepared to evaluate the MS/MS response for neat standards of 
two analytes (dFdC and dFdU) and internal standard. The second set (set B) was prepared 
in plasma extracts taken from six different donors. The third set (set C) was prepared in 
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plasma from the same six sources as in set B, but the plasma samples were spiked before 
extraction. By comparing absolute area of set B against those of set A, the matrix effect 
(ion suppression or enhancement) associated with a given lot of plasma can be measured. 
Similarly, the recovery was determined by comparing the mean peak areas of dFdC, 
dFdU and internal standard obtained in set C to those in set B at a given concentration. 
 
 
2.3.5.3. Gemcitabine Triphosphate in the Cell 
The stability of dFdCTP was of concern when the white cells were treated with strong 
acid (HClO4). Different situations were tested for optimizing the sample preparation. We 
tested how long dFdCTP is stable in strong acid environment (HClO4, 0.4 M). What was a 
better choice of ratio of hydroxide potassium (KOH) to HClO4 for neutralizing the acidic 
cellular supernatant after nucleotide extraction? Finally, we further tested how long 
neutralized dFdCTP would be stable in room temperature while queuing for HPLC 
analysis.  
 
2.4. Results and Discussion 
2.4.1. Gemcitabine and dFdU in Human Plasma 
2.4.1.1. Chromatographic Separation 
Liquid chromatography-tandem mass spectrometry has advantage for its excellent 
specificity in biopharmaceutical analysis. In most cases, chromatographic separation is 
considered by analytical scientists to avoid the possible ion suppression or enhancement 
during method development. In addition, another aspect has to be kept in mind for dFdC 
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and dFdU quantification due to very small mass difference between their parent ions with 
[M+H]+ as 264 amu for dFdC and 265 amu for dFdU as well as their daughter ions with 
mass transition as 264.0/112.1 for dFdC and 265.1/113.2 for dFdU. Hence, 
chromatographic conditions should be optimized to achieve good separation, optimized 
peak shape as well as ion interference free according to following aspects. 
Firstly, an optimized gradient mobile phase was needed to elute the dFdC and dFdU with 
baseline separation. Various pH values of mobile phases, organic modifiers, and elution 
modes were studied for optimization of baseline separation and run time. Since dFdC is a 
weak base with pKa values of 3.6. [126] it would exist mainly as a free base when pH value 
was greater than 5.6. Peak tailing of dFdC in reversed phase HPLC column was 
minimized by adjusting the pH of mobile phase to pH 6.8 with 10 mM ammonia acetate 
buffer. Methanol rather than acetonitrile was used because acetonitrile elutes dFdC too 
rapidly. A gradient elution mode was adopted for baseline chromatographic separation 
since the hydrophilicity of dFdU was much weaker than those of dFdC. This difference in 
their hydrophilic properties is mainly attributed to amine group in cytosine ring. (Fig.1). 
With the optimized chromatographic conditions described, dFdC and dFdU were eluted 
at about 7.5 and 9.4 min, respectively.(Fig 2) More importantly, a minor isotope peak of 
dFdC did not interfere with the quantification of dFdU due to the optimized baseline 
separation. Hence, these optimized chromatographic conditions guaranteed an excellent 
specificity for this quantitative method.  
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                Figure 2.2 The chromatograms of dFdC (upper) and  
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2.4.1.2. Method Validation of dFdC and dFdU 
A simple sample preparation with protein precipitation was used and this was suitable for 
dealing with a large sample size in a short period. Although nitrogen gas drying was 
needed following the protein precipitation, the process was fast due to a small plasma 
sample volume (50 µl) and high percentage (4:1, Acetonitrile/plasma in volume) of 
acetonitrile used. Moreover, there was good recovery for all three compounds. The mean 
recovery for these three compounds ranged from 92-98.3% (Table 2). In addition, matrix 
effect was evaluated through quantification of QC1 and QC2 spiked in six blank human 
plasmas.  
 
Table 2.2 Intra-day and inter-day precision and accuracy for dFdC and dFdU  
(n = 5)   
 
 
The matrix effect [ME(%)] was calculated according to the formula mentioned 
experimental section. No serious matrix effect was observed under our optimized 
chromatographic conditions with ESI (electrospray ionization) interface using six patient 
control plasma samples (Table 2.3). Good linearity was achieved for concentration ranges 
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of 5-2,000 ng/ml for dFdC and 50-20,000 ng/ml for dFdU based on the current LC-
MS/MS conditions. The correlation coefficients r2 for dFdC and dFdU were 0.9969 (95% 
confidence interval, 0.9957-0.9981) and 0.9980 (95% confidence interval, 0.9969- 
0.9990), respectively. The lower limit of quantitation was 5 ng/ml and 50 ng/ml for dFdC 
and dFdU, respectively. This LC-MS/MS method is much sensitive than our previous 
HPLC-UV assay by using as little as 50 µL of human plasma. Their signal-to-noise ratios 
are 8.6 and 7.3, respectively. The assay sensitivity was more than adequate for all clinical 
samples with the last sampling time of 120 min after the end of dFdC infusion.  
 
Table 2.3 Matrix effect and recovery tested in patient control plasma at two 
concentration levels (n = 6). 
 
Set A: Neat standards of two analytes (dFdC and dFdU) and internal standard were 
dissolved in mobile phase; Set B: dFdC, dFdU and internal standard were dissolved 
in plasma extracts taken from six different donors; Set C: dFdC, dFdU and internal 
standard were spiked in plasma from the same six sources as in set B, then the 
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The accuracy and precision of this method were evaluated from the QC samples. The 
precision and accuracy of dFdC and dFdU for QCs were listed in Table 2. The intra and 
inter-day precisions for dFdC and dFdU were ≤9 and ≤13 and their accuracy ranged from 
94 to 102 for quality control samples. 
The sample stability was judged by decrease of sample concentrations after one year 
storage of plasma samples at -20 ºC. Both dFdC and dFdU showed good stability 
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Figure 2.3 Standard Curve for dFdC (upper, n = 3) and dFdU (lower, n = 3) 
 
 
Chapter II:BIOANALYTICAL METHOD DEVELOPMENT 
 49
This LC-MSMS method is much more sensitive than our previous ion-pair HPLC 
method16 where most concentrations of the last sampling point (2 h) are below its LLOQ 
of gemcitabine (80 ng/mL). The method has been successfully used in multi-centre 
clinical trial of dFdC at a dosage of infusional dFdC given at a constant rate of 10 
mg/m2/min over 75 min or at 1000 mg/m2 in 30-min, when combined with a fixed dose 
of carboplatin. The sensitivity of this method is 16 fold higher than our previous HPLC-
UV method. [123] More importantly, a micro-volume of plasma (50 µL) is needed so that it 
is suitable for pediatric clinical trials since the safety of dFdC treatment in children has 
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2.4.2 Gemcitabine Triphosphate 
2.4.2.1 Chromatographic Separation 
Figure 2.4 shows a clear baseline chromatographic separation of dFdCTP from other 
cellular endogenous substances such as ATP which was eluted at 17.5 min.   
 




2.4.2.2 Method validation for determination of gemcitabine triphosphate 
Figure 2.5 showed a good linearity for quantitation of dFdCTP in saline. Due to the 
difficulty in getting human WBC, one of NPC cell line, HONE1, was used for method 
validation. According to validation table 2.4, the intra-run and inter-run were well 



















































2.4.2.3. Optimization of dFdCTP extraction from human WBC  
Initially, 10 µM dFdCTP in PBS was used for stability testing. When treated with HClO4 
(0.4 M) alone, dFdCTP would degrade quickly after 15 min whether on ice or in room 
temperature. In contrast, the alkalined dFdCTP was very stable (Figure 2.6).  
 
























 Figure 2.6 Stability of dFdCTP in solution of HClO4 (0.4M) alone and various 
concentrations of KOH 
 
In order to evaluate the stability of dFdCTP for a longer time, two different 
concentrations of KOH (0.4M, 0.8 M) were tested. When HClO4 solution was neutralized 
with an equivalent concentration of KOH (0.4 M), dFdCTP became more stable 
compared to that in HClO4 solution. Although dFdCTP degraded slowly at first 5 hours, 
the percentage of degraded dFdCTP would degrade 10% after 11.5 hours and up to 36% 
after 24 hours (Figure 2.7). By increasing the concentration of KOH from 0.4 to 0.8 M, 
the stability of dFdCTP improved tremendously with decreased degrade rate of dFdCTP 
to 8.5 % from 36.2 % after 24 hours. Using this HClO4 (0.4 M)/ KOH (0.8 M), the 
prepared samples were stable for at least 12 hours (Figure 2.7) suitable for overnight 
storage of samples in room temperature for injection.  
 





















HClO4/KOH (1:1) HClO4/KOH (1:2)
 
Figure 2.7 Stability of dFdCTP in mixture solution of HClO4 (0.4M)/ KOH (0.4M) 
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2.5. Conclusions 
A highly sensitive LC-MS/MS method was validated and applied to a Phase II clinical 
plasma determination of gemcitabine and its deaminated metabolite. The sensitivity of 
this method is 16 fold greater than our previous HPLC-UV method. More importantly, 
only a micro-volume of plasma is needed so that it is suitable for pediatric clinical trials. 
In addition, a simple sample preparation procedure with acetonitrile precipitation is 
advantageous for high-throughput analysis for a multi-centre clinical trial context. Its 
simplicity and sensitivity will greatly improve the clinical applicability.  
Several studies have indicated that in vitro and in vivo efficacy of gemcitabine may be 
closely correlated to the intracellular accumulation of dFdCTP. Therefore, a sensitive and 
accurate analytical method is critical for oncologists and scientists to optimize the 
treatment scheduling. This intracellular dFdCTP quantitation is a platform for oncologists 
to evaluate the pharmacokinetics of gemcitabine more efficiently and provide a useful 
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3.1. Introduction 
Gemcitabine is a prodrug. It is transported through the cell membrane via nucleoside 
transporters because it is highly hydrophilic. [106] Gemcitabine is converted to its active 
phosphorylated metabolites, dFdCDP and dFdCTP or to inactive metabolites like 
dFdUMP and dFdU within the cell. The cytotoxicity of gemcitabine is highly dependent 
on the accumulation of dFdCTP since this metabolite is the main component (more than 
95%) in the active metabolite pool. [127] The mechanisms of action of dFdCTP include its 
incorporation into DNA chain to stop DNA synthesis in S phase of cell proliferation cycle 
and competition with deoxycytidine triphosphate (dCTP) to inhibit DNA polymerase. [14] 
Thus, the efficacy of gemcitabine is mainly determined by accumulation and retention of 
intracellular dFdCTP.  
Another minor active metabolite, dFdCDP, is a potent inhibitor on ribonucleotide 
reductase. It exerts its anticancer effect through decreasing dCTP pool by inhibiting the 
activity of ribonucleotide reductase. This will interfere with DNA synthesis indirectly.  
Many factors are involved in the active conversion of gemcitabine to dFdCTP. 
Deoxycytidine kinase catalyses the rate-limiting reaction of gemcitabine activation which 
involves phosphorylation to gemcitabine monophosphate (dFdCMP). According to 
Michaelis-Menten Equation (V = Vmax[S]/([S]+Km), [S] being substrate concentration), 
dCK will be saturated when substrate (gemcitabine) concentration, [S], is much greater 
than Km. In this case, V ≈ Vmax. This means that dFdCTP concentration will be 
expected to reach a plateau after a period of exposure with a certain concentration of 
gemcitabine in cell culture. The minimum concentration which saturates dCK is defined 
as the cut-off value for gemcitabine. Accordingly, this concentration is considered 
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optimal to achieve maximum treatment effect.  
In this section, we designed an in vitro experiment to define this optimal concentration of 
gemcitabine in culture medium.  
An additional objective of this in vitro experiment was to study the synergistic activity of 
histone deacetylase inhibitor (PXD101) with gemcitabine cytotoxicity on NPC and 
NSCLC cell lines. The determinants of sensitivity and resistance to gemcitabine are not 
fully elucidated. Many factors involving intracellular dFdCTP and dFdCDP accumulation 
and metabolism can affect the efficacy of gemcitabine. Although several papers have 
proposed possible mechanisms of gemcitabine intrinsic and acquired resistance, the 
progress on reversing this resistance is very limited, especially for clinical strategy.  
PXD101 is one of novel histone deacetylase inhibitors (HDACi) which acts through 
disturbing tumour growth via regulating histone acetylation and restoring silenced tumor 
suppressor genes. However, the HDACi-regulated genes necessary and/or sufficient for 
their biological effects remain undefined. At the moment, PXD101 is undergoing phase II 
clinical trials in a variety of disease indications including hepatocellular carcinoma. 
Recently, several papers reported that PXD101 can potentiate several current 
chemotherapeutic agents such as 5-FU, paclitaxel and carboplatin in vitro and in vivo. [128, 
129] Two histone-deacetylase inhibitors, trichostatin A and SAHA, were also reported to 
enhance gemcitabine-induced cell death in pancreatic cancer. [130, 131] This prompted us to 
test if a novel HDAC inhibitor, PXD101, could produce a synergistic effect with 
gemcitabine on other tumours e.g. NPC and NSCLC. 
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3.2. Objectives 
z To evaluate the incubation time of gemcitabine on the effect of intracellular 
dFdCTP accumulation; 
z To determine the minimum concentrations of gemcitabine in culture medium that 
optimize intracellular dFdCTP accumulation; 
z To screen sensitivity of different cell lines to gemcitabine or gemcitabine 
combined with PXD101; 
z To explore the mechanism of the synergistic effect of gemcitabine and PXD101 
on different cell lines. 
 
3.3. Materials and Methods 
3.3.1. Drug and chemicals 
Gemcitabine hydrochloride (dFdC, LY 264368), Gemcitabine Triphosphate (dFdCTP, LY 
264368) were kindly provided by Eli Lilly & Co. (Indianapolis, IN, USA). The internal 
standard, Gemcitabine-13C, 5N2 Hydrochloride, was purchased from Toronto Research 
Chemical (Canada), Tetrahydrouridine (THU) was purchased from Biosciences, inc. La 
Jolla, CA 92039-2087.  MTS + PES reagent (CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay, Promega, USA). PXD101 (N-hydroxy-3-[phenylsulphamoylphenyl] 
acryl amide) was kindly provided by TopoTarget (Oxford, UK). RPMI-1640 media 
(GIBCO, Invitrogen corporation, USA); Fetal Bovine Serum (Sigma, St Louis, MO, 
USA; 100 U/ml penicillin (GIBCO, Invitrogen corporation, USA); 100 µg/ml 
streptomycin, USA); Phosphate-buffered saline (PBS) (NUMI, National University of 
Singapore). Propidium iodide (PI) and Triton X-100 were purchased from Sigma-Aldrich 
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(USA). HPLC grade methanol and 70% ethanol were purchased from Merck Darmstadt 
(Germany). All other chemicals were of analytical grade and commercially available, 
unless otherwise specified. 
 
3.3.2. Cell lines and cell culture 
Nasopharyngeal carcinoma cell lines include CNE1, HK1, HONE1 and Lung Cancer cell 
lines include H1299 and H292 were provided Dr Hsieh from Singapore Johns Hopkins 
International Medical Centre.  
Cells were routinely grown in culture in RPMI 1640 medium containing of 10% fetal 
bovine serum and 100 units /ml penicillin and 100 µg/ml streptomycin. The cells were 
kept growing at 37 °C in an incubator in a humidified atmosphere containing 95% air and 
5% CO2. 
 
3.3.3. Growth inhibition study 
1. Seeding the cells in triplicate in 96-well plate. The plating cell number was set as 
2000-2500 cells/well except for HK1(5000 cells/well); 
2. Cell suspension was prepared at cells density of 25,000 cells/ml and 50,000 
cells/ml for HK1 with 100 µl of cell suspension for each well of 96-well plate; 
3. After incubating 24 hrs, 100-µl drug solution or blank medium was added into 
each well of 96-well plate; 
4. 48 or 72 hours later, 20 µl of MTS/PES was added into each well for incubation 
for 3 hours;  
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5. Measurement of OD value on wavelength 490 nm with reference wavelength set 
at 650nm; 
6. At least five drug concentrations were used to determine the IC50 values. 
 
 
3.3.4. dFdCTP and dFdC quantitation 
Analytical determinations of dFdCTP and dFdC were the same as those described in 
Chapter II. The only difference was that the samples are from in vitro experiment. Sample 
collection and preparation were described as follows. 
 
3.3.4.1. dFdC sampling and preparation 
Eppendorf tubes (1.5 ml) were prepared for culture medium sample collection by adding 
50 µl of THU (cytidine deaminase inhibitor) solution and stored in a covered box at -20 
°C. The sampling times were as follows: 
 
Table 3.1 Culture media sampling time point for determination of dFdC 
Unit Minutes hours 
Time point 0 10 20 30 1 1.5 2 3 4 6 8 24 30 48
 
 
These samples were used for determination of dFdC concentration left in the medium at 
different incubation time. At above mentioned time points, 50 µl of medium from the 
culture flask (75 ml containing 15-ml medium) was transferred into a THU containing 
Eppendorf tube. After centrifuging at 10,000 g for ten minutes, the 90-ul supernatant was 
transferred into HPLC insert and 20 ul supernatant was injected into LC-MSMS system 
Chapter III: In vitro Study of Gemcitabine 
 62
for quantifying dFdC and using established LC-MSMS method. A series of calibrators in 
blank media for dFdC were prepared to establish standard curves. 5 µl of Gemcitabine-
13C, 5N2 (5 ug/ml) was added into each tube as internal standard. Since the sample 
collected in Eppendorf tube was diluted, the final concentrations should be equal to 2-
fold calculated concentrations.  
 
3.3.4.2. Cell harvesting and preparation  
The cell pellets were collected at 1, 4, 8, 24 and 48 hrs for determination of dFdCTP 
accumulation after incubation with various concentrations of gemcitabine in the culture 
medium. The cells were trypsinized and washed with PBS. After centrifugation at 200 g 
for 5 min, the supernatant was fully discarded. Then, 100 µl PBS was added into the 15 
ml centrifuge tube and the cell pellets were homogenized and transferred into another 
Eppendorf tube. This tube was frozen immediately in liquid nitrogen and then stored in 
freezer at - 80°C for dFdCTP quantitation.  
The sample for HPLC analysis was prepared according to the following protocol. 
i). Add 80 µl of HClO4 (1M) into cell pellet containing tubes; 
ii). Vortex for 30 seconds; 
iii). Centrifuged at 10,000 g for 2 min; 
iv). Transfer the supernatant into another Eppendorf tube containing 30 ul of KOH (3 M); 
v). Vortex 30 seconds; 
vi). Kept on ice for 20 minutes; 
vii). Centrifuged at 10,000 g for 5 min; 
viii). 100 µl of supernatant was injected into HPLC system for analysis. 
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3.3.5. Titration of gemcitabine concentration for maxium accumulation of dFdCTP 
A nasopharyngeal carcinoma cell line, HONE1, was used as the in vitro model to 
evaluate the effects of gemcitabine’s exposure concentrations in culture medium and 
incubation time on the accumulation of dFdCTP inside the cells. In this study, the 
concentrations of gemcitabine used were increased from 2 µM to 100 µM. The 
incubation time was set at 1, 4, 8, 24 and 48 hr. At each time point, the cells were 
trypsinized and collected for determination of intracellular dFdCTP and dFdC 
concentrations as described previous section 3.3.4.  
 
3.3.6. Combination Study 
In order to evaluate the drug interaction, two methods were used to measure the the effect 
of PXD101 on cytotoxicity of gemcitabine; the Modulate Effect for enhancement or the 
Combination Index for antagonistic, synergistic or additive effect .  
For enhancement effect of PXD101 on gemcitabine’s anticancer activity, the Modulate 
Effect (ME%) was defined as:  
Modulate Effect (%)= (IC50 of dFdC/IC50 of dFdC combined with PXD101)×100 
The Combination Index (CI) was defined as: 
Combination Index (CI) = (Am)50/(As)50 + (Bm)50 + (Bs)50 
Where (Am)50 is the concentration of drug A necessary to achieve 50% inhibitory  
effect in the combination; (As)50 is the concentration of the same drug that will  
produce the identical level of effect by itself; (Bm)50 is the concentration of drug B  
that will produce a 50% inhibitory effect in the combination, and (Bs)50 is the  
concentration of drug B that will produce the same level of effect by itself. 
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CI > 1 indicates antagonism;  
CI < 1 indicates synergy; and 
CI = 1 indicates an additive Effect [132] 
 
3.3.7. DNA content measurement 
Fix cells with ethanol 
1. Prepare the fixative by filling 12×75 mm-centrifuge tubes with 4.5 ml of 70% ethanol. 
Keep tubes on ice. 
2. Collect cells and suspend 106 to 107 cells in 5 ml PBS in a centrifuge tube. 
3. Centrifuge cells 6 min at 200 g. 
4. Thoroughly re-suspend cells in 0.5 ml PBS using a Pasteur pipette. (Note: It is 
important to achieve a well-dispersed suspension). 
5. Transfer the cell suspension into the tubes containing 70% ethanol. Keep cells in 
fixative ≥ 2 hrs. (Note: Cells suspended in 70% ethanol can be stored at 0 °C to -20 °C 
for several months). 
Stain cells with propidium iodide (PI) 
6. Centrifuge the ethanol-suspended cells 5 min at 200 g. Decant ethanol thoroughly. 
7. Suspend the cell pellet in 5 ml PBS, wait 60 seconds and centrifuge 5 min at 200 g. 
8. Suspend cell pellet in 1 ml PI/Triton X-100 staining solution with RNase A. Keep 
either 15 min at 37 °C or 30 min at room temperature. 
Perform Flow Cytometric Analysis 
9. Set up and adjust the flow cytometer for excitation with blue light and detection of PI 
emission at red wavelengths. 
Chapter III: In vitro Study of Gemcitabine 
 65
10. Measure cell fluorescence in the flow cytometer. Use the pulse width-pulse area 
signal to discriminate between G2 cells and cell doublets and gate out the latter.  
11. Analyze the data using DNA content frequency histogram deconvolution software. 
 
3.4. Results and discussion 
3.4.1. Gemcitabine’s chemical stability in culture medium without cells 
Gemcitabine (20 µM) was incubated in culture medium in incubator at 37 °C for 5 days. 
100-µl media containing gemcitabine were sampled at the start point, 24 h and 120 h 
after incubation. The drug analysis was processed with HPLC-UV. The result showed that 
gemcitabine was stable at least for 5 days in the cell culture incubation condition (Figure 
3.1.) 
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3.4.2. Gemcitabine’s sensitivity on NPC cell lines 
Gemcitabine’s sensitivity on NPC cell lines were shown as follows (Table 3.2). 
Gemcitabine was active against all three NPC cell lines. HK-1 was the most sensitive, 
followed by HONE1 and CNE-1. The Cmax of gemcitabine in the clinical setting could 
be as high as 64.6 µM when dosed at 1000 mg/m2 with 30 min infusion but the Cmax for 
fixed dose rate infusion of gemcitabine were reduced significantly to the range of 18-35 
µM (Table 1.1). Thus, we could conclude that NPC cell lines were sensitive to 
gemcitabine in vitro since their IC50 values are much less than the generally acceptable 
target 10-20 µM plasma concentration for gemcitabine. [15, 133] 
 
Table 3.2 IC50 of NPC cell lines to gemcitabine after 72 h incubation 
NPC Cell lines HK1 HONE1 CNE1 
(n = 3) 
IC50 ± SD (µM) 
 
1.30 ± 0.23 2.10 ± 0.38 2.62 ± 0.41 
 
 
3.4.3. Impact of incubation time on IC50 of gemcitabine for HK1 
Incubation time was expected to be an important factor on the drug activity since 
gemcitabine is a prodrug and time would be required for it to be transported and 
converted into its active metabolites inside the cells. In order to understand the effect of 
time course on gemcitabine’s activity, HK1 was used as the cell model to evaluate the 
role of incubation time on IC50 of gemcitabine. HK1 cells were incubated for various 
incubation times ranging from 4h to 72h. The IC50 values were labeled in Figure 3.2. The 
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results showed that IC50 values of gemcitabine changed dramatically in terms of 
incubation time. If the incubation time was equal to or less than 24 hrs, the IC50 could not 
be attained up to 100 µM gemcitabine. When the incubation time was increased to 48 hrs, 
the IC50 value was dramatically decreased to 2.6 µM. If the incubation time was further 
increased to 72 hrs, the IC50 was decreased to 1.3 µM which was only half of that with 48 
h incubation. This phenomenon might be because that gemcitabine itself is a produrg 
which needed to be converted into its active metabolites, gemcitabine diphosphate and 
triphosphate, to play the effects against cancer cells through inhibiting ribonucleotide 
reductase and stopping DNA elongation. Besides, gemcitabine produced a pro-apoptosis 
effect on cancer cells through interfering S-phase transition.  
 





Chapter III: In vitro Study of Gemcitabine 
 68
3.4.4. Effect of incubation time and concentration of dFdC on intracellular 
accumulation rate of dFdCTP using HONE1 cell model  
We have learned from the IC50 values of gemcitabine with HK1 cells experiment that 
incubation time is a key factor on cell proliferation. However, we have no idea on the 
kinetics of dFdCTP accumulation during the incubation period. Since gemcitabine’s 
activation involved multiple steps, and exposure time would be expected to play an 
important role on its activity through modulating the intracellular accumulation and 
elimination of dFdCTP. This effect was evaluated through determining kinetic change of 
dFdCTP concentrations using various concentrations of gemcitabine. HONE1 cell line 
was used because it would grow faster than HK1 cells. The cells were incubated with the 
indicated concentrations of dFdC, the accumulation concentrations of dFdCTP were 
measured after variable incubation times. There was an increase in intracellular 
concentration of dFdCTP with increasing concentrations of dFdC in culture medium. Our 
finding was similar to the results from other investigators. [14] But the accumulation of 
dFdCTP reached a plateau after 8 h incubation when the initial incubation concentration 
of dFdC was 10 µM or above. After 8 h incubation, the intracellular concentrations of 
dFdCTP were shown to peak in the indicated time points (Figure 3.3). This implied that 
the activation process of dFdC to dFdCTP might be saturable at this point, assuming that 
Vmax was reached. The concentration of substrate (dFdC) had no influence on formation 
rate of dFdCTP.  
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Figure 3.3 Effect of incubation time on the accumulatin of dFdCTP in HONE1 with 
various concentrations of gemcitabine. 
When the incubation time was extended to 24 h, dFdCTP could not be detected in the cell 
pellets exposed to 2 µM of dFdC. There were two postulated reasons for this 
phenomenon. The first one was that the elimination rates of dFdCTP showed different 
kinetic characteristics, linear elimination was proposed for low concentrations of 
dFdCTP. And elimination seemed to become saturated at high concentrations of dFdCTP. 
[127] We could expect that the elimination rate of dFdCTP was fast when the initial 
concentration of dFdC in culture medium was less than 50 µM. For example, when dFdC 
was at 2 µM, all the dFdCTP inside the cells would be completely eliminated and finally 
converted to its non-active metabolite (dFdU) after a certain time (24 h) (Figure 3.3). 
However, we could observe that dFdCTP elimination pattern was changed when dFdC 
concentration was ≥ 50 µM. Over exposure dFdC could induce an inhibition of 
deaminase, resulting in a decrease of dFdCTP catabolism. The elimination could be 
switched to concentration-dependent kinetics from linear elimination. If the incubation 
time was further increased up to 48 h, the dFdCTP was only detected in the cells with 
equal or greater than 20 µM of dFdC and dFdCTP showed a similar concentration for 
Chapter III: In vitro Study of Gemcitabine 
 70
both 50 and 100 µM dFdC. On the other hand, the intracellular dFdCTP concentrations 
were dependent on the constant exposure of dFdC in the culture medium. With increase 
of dFdC concentrations, an exposure window for dFdC at a minimum 2 µM would be 
increased significantly (Figure 3.4). This could provide enough dFdC for intracellular 
phosphoralation.  










































Figure 3.4 Kinetics of dFdC in culture medium for variable incubation 
concentrations of gemcitabine (upper: full concentration scale; lower: enlarged 
for concentrations below 5 µM). 
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3.4.5. Effect of dFdC concentration on cell viability with an increasing exposure time 
In order to understand the association of dFdCTP accumulation with cell viability, the 
cultured cells were trypsinized and counted at indicated time points. The cells were 
incubated in 5% of trypan blue. Then the total cell number and viable cell number were 
counted under microscope. The viability was calculated by the ratio of viable cell number 
versus total cell number. The cell viabilities for cells incubated in various concentrations 
of dFdC were shown in Figure 3.5. When incubation time was ≤ 8 h, cell viability would 
be maintained at a relatively high level. No difference existed among different 
concentrations of dFdC. With the increase of incubation time, the cell viability decreased 
quickly, especially for those cells incubated in 10 µM or higher concentration of dFdC. 
However, the cell viability values were nearly the same when the concentrations of dFdC 
were in the range of 10 to 100 µM. This trend was in accordance with the results of 
dFdCTP accumulation. It was found that the cell’s survival was mainly dependent on the 
exposure durations of dFdC rather than its incubation concentrations as long as the 
concentrations of dFdC were above 2 µM during incubation. In addition, a high initial 

































Figure 3.5 The influence of incubation time and gemcitabine concentration on the 





3.4.6. Combination of gemcitabine with PXD101 
As a novel HDAC inhibitor, PXD101 showed a good anticancer activity with a tolerable 
toxicity. It has been used as a single agent in several tumors in the clinical setting. At the 
same time, various combinations with other current anticancer agents are being explored 
and some of these combinations have been confirmed as effective combination with 
synergistic effects.  
In this study, we investigated the efficacy of gemcitabine and PXD101 combination using 
different cell models including CNE1, H292 and H1299. CNE1 is one of NPC cell line 
and H292 and H1299 are NSCLC cell lines. Since gemcitabine was also used clinically 
for NPC and NSCLC, therefore the results would potentially be relevant for planning 
future clinical trials.  
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3.4.6.1. CNE1 cell model 
Gemcitabine was shown to be active to CNE1 with IC50 of 2.61 µM after 72 h incubation. 
This concentration is within the clinical therapeutic range. If CNE1 cells were exposed to 
2 µM of PXD101 together with different concentrations of gemcitabine simultaneously, 
the IC50 of gemcitabine was dramatically decreased to 0.48 µM (Figure 3.6). The 
enhancement effect was obvious with a modulate effect of 5.3 (Modulate Effect = IC50 of 
dFdC / IC50 of dFdC+PXD101 = 5.3). 
.  
  Figure 3.6 IC50 of gemcitabine to CNE1 with PXD101 (2 µM) after 72 h  
 
3.4.6.2. H292 cell model 
H292 is one of non-small cell lung cancer cell lines and has been frequently used as a 
lung cancer model. In order to evaluate the synergistic effect of gemcitabine and PXD101 
on lung cancer, we measured the IC50 values of gemcitabine in single or combination 
with PXD101 (2.5 µM). After 72 h incubation, the IC50 values were 3.5 µM and 0.43 µM 
for gemcitabine alone and gemcitabine and PXD101 combination, respectively. Thus, the 
modulate effect can be calculated as follows: 
Modulate Effect = IC50 of dFdC / IC50 of dFdC+PXD101 = 8.1 
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According to clinical pharmacokinetic parameters of PXD101 in human plasma, the peak 
concentration could reach up to 200 µM. The concentrations of PXD101 in patients’ 
plasma were kept at a concentration higher than 2.5 µM for the first 2 hours when the 
dosage administered was 1200 mg/m2 by 30 min i.v. infusion according to our phase I 
trial. In addition, PXD101 at this dosage (1200 mg/m2) was also well tolerable by cancer 
patients in our current Phase I study on hepatocarcinoma. Thus, 2.5 µM of PXD101 was 
expected to have very mild toxicity but efficacious when used as single agent. We used 
this concentration of PXD101 (2.5 µM) to test the synergistic effect .The results showed 






































Gemcitabine + 2.5 uM PXD101 Gemcitabine
 
  Figure 3.7 IC50 of gemcitabine alone to H292 and IC50  




This synergistic effect was further confirmed with cell morphological characters and cell 
density (Figure 3.8). The cells in A are H292 without any treatment after 72 h incubation. 
The cells in B are H292 treated with 5 µM of gemcitabine alone after 72 h incubation. 
The cell proliferation was inhibited by gemcitabine at 5 µM but there was no obvious 
3.5 0.5 
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change on cell morphology. The cell in C is H292 treated with 2.5 µM of PXD101 after 
72 h incubation. The cell proliferation was also inhibited like that in B. However, a 
significant difference was shown in D using the combination. The cell density was much 
less compared to those treated with either single agent. This indicated that the cell growth 
was not only inhibited but the cells were killed by this combination of gemcitabine and 
PXD101.  
 
Figure 3.8 Microscope observation on H292 treated with indicated  




A: Control (no treatment) B: dFdC (5uM) 
C: PXD101 (2.5uM) D: dFdC (2.5uM) + PXD101 (2.5uM)
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As discussed in previous parts, the synergism was detected between gemcitabine and 
PXD101. In order to understand the mechanism, a DNA content experiment was designed 
to observe cell cycle change as well as percentage of the apoptosis cell population. The 
results were shown in Figure 3.9. M1, M2, M3 and M4 represent sub G1, G1, S and 
G2/M, respectively. For the control cell (without any treatment), there was no cell in sub 
G1. When the cell was treated with gemcitabine (5 µM) alone, the G1 was significantly 
decreased and the S phase increased. This indicated that the DNA synthesis in S phase 
was blocked when the cell was treated with gemcitabine. On the other hand, high 
percentage of sub-G1 resulted in cell apoptosis. When PXD101 alone was used, the 
obvious change was that a relative high of G2/M was observed. This implied that the cell 
was mainly on G2/M arrest. Lastly, the combination of gemcitabine and PXD101 resulted 
in significant apoptosis and S phase arrest.    
 
Figure 3.9 Flowcytometry of H292 treated with indicated drugs 
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3.4.6.3. H1299 cell model (Drug resistant NSCLC) 
p53 being one of tumor-suppressor genes, responsible for directing repair of damaged 
DNA or committing a cell to apoptosis, is mutated or otherwise altered in more than 50% 
of lung cancers, including 40% to 70% of non-small cell lung cancers. A majority of 
clinical studies suggested that lung cancers with p53 alterations carry a worse prognosis 
and lack of p53 is an important factor attributed to drug resistance. H1299 is a NSCLC 
cell line without p53 expression. Any novel chemotherapy would have high clinical 
implication if its potency could be demonstrated in p53 mutant or null cell lines like 
H1299. Herein, we tested the combination of gemcitabine and PXD101 on the 
cytotoxicity on H1299. In order to measure the combination index (CI), the IC50 values of 
gemcitabine and PXD101 were measured separately. The IC50 of PXD101 is 3.2 µM for 




























The IC50 value of gemcitabine on H1299 was 88.99 µM (Figure 3.11). In combination 
study, PXD101 was fixed as half of its IC50 (1.6 µM). A serial of gemcitabine 
concentration was applied to test the IC50 of gemcitabine combined with 1.6 µM of 
PXD101. In this case, the IC50 value was dramatically decreased 6898 fold from 89 µM 
to 0.013 µM. This experiment demonstrated the combination of gemcitabine and 
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   Figure 3.11 IC50 of gemcitabine combined with 1.6 µM  
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The modulate effect and CI were calculated and listed as follows (Table 3.3.). Obviously, 
this enhancement effect was much more significant than p53 wild-type cell (H292). CI 
was equal to 0.5001. This also suggested a very strong synergistic effect of gemcitabine 
and PXD101 on H1299.  
 
 





This strong synergistic effect was also confirmed through microscope observation (Figure 
3.12). The cell in A is H1299 without any treatment after 72 h incubation. The cell in B is 
H1299 treated with 5 µM of gemcitabine alone after 72 h incubation. The cell density 
was less compared to control but a quite number of cancer cells still survived after being 
exposed to 5 µM of gemcitabine for 72 h. The cell in C is H1299 treated with 2.5 µM of 
PXD101 after 72 h incubation and the cell density was in the same magnitude as in B. 
The cell morphology looked undamaged after being incubated in 2.5 µM of PXD101 for 
72 h. However, the situation was changed significantly in drug combination D. The cell 
morphology was changed and the cell density was much less compared to those treated 
with either single agent. The results indicated that this combination of gemcitabine and 
Drug IC50 (µM) Modulate Effect (%) Combination Index
PXD101 3.2 NA NA 
Gemcitabine 88.99 NA NA 
Gmcitabine+ PXD101 0.0139 6898 0.5001 
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PXD101 was effective for tumor cells regardless to the status of p53. In terms of 
overcoming drug resistance, this finding has an important clinical implication to 
identifying the combination of gemcitabine and PXD101 as a promising combination for 
further evaluation NSCLC. 
 
 
Figure 3.12 Microscope observations on H1299 treated with indicated 





B: dFdC (5µM) 
C: PXD101 (2.5µM) 
A: Control (no treatment)
D: dFdC (2.5µM) + PXD101 (2.5µM) 
Chapter III: In vitro Study of Gemcitabine 
 83
The cell cycle changes of H1299 were shown as follows (Figure 3.13). For the control 
cell (without any treatment), there was no cell in sub G1 phase. When the cell was treated 
with gemcitabine (5 µM) alone, some portion of G1 was shifted to S phase and G2/M 
was obviously decreased. This indicated that the cells were arrest in S Phase and DNA 
synthesis was blocked when the cell was treated with gemcitabine. At the same time, a 
significant increase in sub-G1 resulted in cell apoptosis. When PXD101 alone was used, 
the cells were arrested at G2/M phase. But the the percentage in sub-G1 was relatively 
lower compared to gemcitabine. However, the combination of gemcitabine and PXD101 
resulted in a significant increase on both cell apoptosis and S phase arrest.    
 
Figure 3.13 Flowcytometry of H1299 treated with indicated drugs 
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Furthermore, the percentage of apoptosis cells was statistically significant higher in 






Figure 3.14 Cell cycle changes of H1299 treated with gemcitabine alone or in 
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3.5. Conclusions 
Our in vitro experimental results suggested that the duration of incubation was the 
determinant for intracellular dFdCTP accumulation when the concentration of dFdC of 
incubation medium was ≥ 2 µM. A plateau concentration of intracellular dFdCTP would 
be achieved after 8 h incubation when initial incubation concentration of dFdC was ≥ 10 
µM. In accordance with this observation, the cell viability was reduced by the same 
magnitude with 48 h incubation when the exposure concentration of dFdC was in the 
concentration range of 10-100 µM. The viability was due to the combined effect of 
dFdCTP accumulation level and retention duration (incubation time). With regards to 
combining PXD101 with gemcitabine, the potent synergistic effect was verified using 
different cell models (NPC and NSCLC) especially with the p53-null resistant lung 
cancer cell line (H1299). This combination would be used in vivo to test its effect on solid 
tumors. This novel combination might have high potential to become a very promising 
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Developments in the clinical administration of gemcitabine are focusing on efforts to 
extend the duration of exposure to the drug to counteract its rapid metabolism in the 
circulation. [134] The infusion of gemcitabine at 10 mg/m2 per min has demonstrated 
increased tumor efficacy in a randomized phase II study of advanced pancreatic 
cancer.[135] A higher median intracellular gemcitabine triphosphate concentration is 
achieved in the fixed dose rate schedule. However, infusion of gemcitabine at a fixed 
dose rate generally results in higher toxicity like increased myelosuppression and hepatic 
dysfunction than a standard 30-min infusion.[86] In addition, more phase II studies of  
infusion gemcitabine at 10 mg/m2 per min have suggested tolerability and a favorable 
response rate in combination with platinum compounds in patients with advanced 
NSCLC have been reported.[136, 137] 
The pharmacologic advantage of administering gemcitabine at a fixed dose rate of 10 
mg/m2/min and the proven efficacy of combination with carboplatin in NSCLC provided 
the basis for our study.  
We conducted a phase I-II study of fixed dose rate (10 mg/m2 per min) gemcitabine in 
combination with fixed AUC-dose carboplatin in patients with advanced-stage NSCLC. 
The study was to establish the maximal tolerated dose (MTD) of gemcitabine, to evaluate 









In this chapter, a phase I clinical trial was conducted to titrate the dosing of infusion 
gemcitabine administered at 10 mg/m2 per min and evaluate the response rates and 
toxicities of this fixed rate infusion of gemcitabine in combination with carboplatin in 
advanced NSCLC. In addition, pharmacokinetic parameters of gemcitabine at different 
doses would be calculated and analyzed. And finally, the toxicities would be associated 
with doses and pharmacokinetic parameters. 
 
4.3. Methodology 
4.3.1. Patient selection 
The eligibility criteria for study entry included histologically or cytologically confirmed 
stage IIIB or stage IV NSCLC. Patients were required to have measurable or evaluable 
disease and to have received one or no prior chemotherapy for advanced disease. 
Previous neoadjuvant or adjuvant chemotherapy, or chemotherapy given concurrently 
with radiotherapy for non-metastatic disease was allowed if the last dose had been 
administered 6 months or more before study entry. Patients who had received prior 
platinum and/or gemcitabine were excluded. Patients with symptomatic central nervous 
system metastases requiring steroid were excluded. Prior radiotherapy was allowed as 
long as the indicator lesion(s) was not within the previous radiation field and the last dose 
of radiotherapy had been completed at least 3 weeks before study entry. Patients were 
required to have a Karnofsky performance status of ≥70%, WBC count ≥3500/µL, 
neutrophils ≥2000/µL, platelet count ≥100,000/µL, hemoglobin ≥9 g/dL, serum 
creatinine 
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<133µmol/L or creatinine clearance >30 ml/min, serum bilirubin not more than 1.5 times 
the upper limit of normal (ULN), serum transaminase levels not more than twice ULN 
(not more than five times ULN if liver metastases were present), life expectancy >3 
months, and age ≥18 years. The study was approved by the institutional review board and 
all patients were required to provide written informed consent. 
 
 
4.3.2. Treatment plan  
Treatment consisted of carboplatin on day 1 followed by fixed dose rate of infusion 
gemcitabine on days 1 and 8 every 21-day cycle. 5-Hydroxytryptamine-3 receptor 
antagonists were routinely used as antiemetics. Prophylactic growth factors were not used 
routinely. Carboplatin was given at a dose to target an area under the curve (AUC) of 5 
mg/ml×min over 1 h. [138, 139] The dosing of carboplatin was calculated according to 
Calvert formula, with AUC of 5 mg/ml×min used as the end point [Dose (mg) = Target 
AUC × (GFR+25)]. The GFR was calculated according to the Cockroft-Gault formula 
[GFR (ml/min) = (140-age) × Body weight (in kg)/0.81 × serum creatinine (µmol/l)]. For 
female, the correction factor is 0.85 (×calculated GFR). Gemcitabine was infused at a 
constant rate of 10 mg/m2 per min. The starting dose level of gemcitabine was 600 mg/m2 
with subsequent 150 mg/m2 increments to 750 and 900 mg/m2. The duration of infusion 

















  Figure 4.1 Treatment doses of gemcitabine 
 
 
The duration of infusion was identical for days 1 and 8 in any individual patient. Doses 
were assigned at registration and no dose escalation was allowed in an individual patient. 
Treatment-related toxicity was evaluated after each cycle. The dose limiting toxicity 
(DLT) was defined based on toxicities experienced during the first cycle of chemotherapy 
only. Cohorts of at least three patients were treated at each dose level. Dose escalation 
proceeded if no patients developed DLT after the first cycle. If one of three patients 
experienced DLT, a further three patients were treated at that level. Dose escalation was 
stopped if one-third of patients at a given dose level developed DLT. The last patient at 
each dose level was evaluated for first cycle toxicity before a new patient was entered 
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grade 4 thrombocytopenia, grade 3 neutropenia with fever or grade 3 thrombocytopenia 
with active bleeding, failure to recover from toxicity to receive a second cycle of 
chemotherapy despite a delay of more than 1 week from the scheduled day and non-
hematologic toxicity of grade 3 or more (except for reversible elevation of transaminases, 
nausea, vomiting and alopecia). MTD was defined as the dose level immediately below 
the level that resulted in at least one-third of patients experiencing DLT. If DLT was 
experienced, responding patients were allowed to continue treatment with dose reduction. 
Dose modifications were based on weekly blood counts and assessment of toxicity. 
Toxicities were graded according to the National Cancer Institute Common Toxicity 
Criteria, version 2. (http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf). On day 22 of 
each cycle, for neutropenia of grade 1 or more and/or platelets <100,000/µL, treatment 
was delayed for 1 week. On day 8 of each cycle, for neutropenia of grade 3 or more and 
thrombocytopenia of grade 2 or more, the gemcitabine dose was reduced by 25% and 
maintained for the next cycle, and for grade 4 neutropenia and/or grade 3/4 
thrombocytopenia, gemcitabine was omitted and then decreased by 25% for the next 
cycle after marrow recovery and carboplatin was also reduced by 10% for the next cycle. 
The nadir count of the previous cycle also influenced dose adjustment for the next cycle. 
Gemcitabine was reduced by 25% and carboplatin by 10% for a grade 4 neutropenia with 
fever, or grade 4 neutropenia for more than 7 days or thrombocytopenia of grade 3 or 
more with bleeding or platelets <25,000/µL. Patients requiring a third dose reduction 
were taken off study. Patients who experienced a non-hematologic toxicity of grade 3 or 
more, except for nausea, vomiting, fatigue and reversible elevation of transaminases, 
were taken off study. 
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4.3.3. Patient evaluation 
Before initiation of chemotherapy, all patients underwent a history and physical 
examination and determination of performance status. A complete blood count with 
differential, serum biochemistry, urinalysis, and ECG were obtained at baseline for each 
patient. Chest radiography, thoracic and abdominal computed tomography (CT) scans 
were performed as required for assessment of measurable or evaluable disease. CT scan 
of the brain and bone scan was performed if clinically indicated. Patients were assessed 
weekly throughout treatment by complete blood count, serum biochemistry and recording 
of toxicities. Tumor response evaluation was performed after every two cycles according 
to the RECIST criteria.[140] Patients with at least stable disease or better continued with 
treatment to a maximum of six cycles. If DLT was experienced, responding patients 
continued treatment with a reduced dose. Patients with progressive disease were 
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4.4. Results  
4.4.1. Patient Characteristics 
A total of 15 patients were enrolled into the study. Their median age was 57 years (range 
35 to 81 years) and 11 were male. Of the 15 patients, 3 and 12 had stage IIIB and IV 
disease, respectively, and 13 had a Karnofsky performance status (KPS) of at least 90% 
and 2 a KPS of 70–80%. (Table 4.1) Adenocarcinoma was the predominant histologic 
subtype (n=10). All patients were chemonaive. All patients were assessed for toxicity. A 
total of 51 cycles were administered. The median number of cycles per patient 
administered was three (range one to six). The relative dose intensities of gemcitabine at 


















Table 4.1 Karnofsky performance scale and explanation 
Scale Summary 
100: Normal, no complaints; no evidence 
of disease 
90:  Able to carry on normal activity; 
minor signs or symptoms of disease 
80: Normal activity with effort; some signs 
or symptoms of disease 
Able to carry on normal activity; no special 
care needed 
70: Cares for self; unable to carry on 
normal activity or to do active work 
60: Reqires occasional assistance but is 
able to care for most of his needs 
50: Requires considerable assistance and 
frequent care 
Unable to walk; able to live at home and 
care for most personal needs; a varying 
amount of assistance is needed 
40: Disabled; requires special care and 
assistance  
30: Severely disabled; hospitalization is 
indicated although death not imminent 
20: Very sick; hospitalization necessary; 
active supportive treatment is necessary 
10: Moribund; fatal processes progressing 
rapidly 
Unable to care for self; requires equivalent 
of institutional or hospital care; disease 
may be progressing rapidly 










At dose level 1, with infusion of gemcitabine over 60 min, no DLT were observed in 
three patients. The MTD was exceeded at dose level 2 (90 min). The DLT observed was 
grade 3 liver failure in one patient and grade 3 thrombocytopenia with hematemesis in the 
second patient. A study amendment was made to include an intermediate dose level (level 
2A) of gemcitabine 750 mg/m2 over 75 min. At this level, one out of six patients 
experienced DLT, which was grade 3 neutropenia with failure to recover in time to 
receive the second cycle of chemotherapy. The frequency of cycle 1 grade 3/4 
hematologic toxicity was low (Table 4.2). However, when all cycles of chemotherapy at a 
given level were analyzed, a different hematologic profile was observed. At level 1 (60 
min), 50% of cycles were complicated by a nadir neutrophil count of grade 3 or 4. At 
levels 2 and 2A, 20% and 43% of cycles, respectively, were complicated by neutropenia 
grade 3 or 4. There were no episodes of febrile neutropenia. Cumulative 
thrombocytopenia, in contrast, was not as frequent (Table 4.3). Non-hematologic side 
effects including fatigue, nausea, vomiting, constipation and fever were mild and not 
dose-dependent (Table 4.4). One patient developed grade 3 vomiting. Aspartate 
transaminase was mildly elevated in six patients but was not clinically significant and 
was reversible. Transient fever and rash were uncommon. One patient developed a non-
hematologic DLT, manifested by grade 3 clinical liver failure (asterixis) at level 2. This 
patient had a previous history of heavy alcohol intake ceasing 5 months prior to study 
entry. At the time of chemotherapy, he had a grade 2 hypoalbuminemia, but liver 
function was otherwise normal. On day 15 of cycle 1 of chemotherapy, he developed 
confusion and asterixis. He had a grade 3 hypoalbuminemia, grade 1 transaminases and 
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grade 2 hyperbilirubinemia. The patient recovered with supportive care but did not 
receive further therapy and was subsequently withdrawn from the study. 
 
 
Table 4.2 Cycle 1 hematologic toxicities by dose level (n = 15) 
Neutropenia grade  Thrombocytopenia grade Dose Level No. of 
patients 1/2 3 4  1/2 3 4 
1 (60 min) 3 1 0 0  1 0 0 
2 (90 min) 6 1 0 1a  1 1a 0 





Table 4.3 Cumulative grade 3/4 hematologic toxicities by dose level  
Numbers in parentheses are the percentage of courses having the indicated toxicity 
(n = 15) 
Neutropenia grade  Thrombocytopenia 
grade 




3 4  3 4 
































Table 4.4 Non-hematologic toxicity (n = 15) 








Elevated alanine transaminase 
Elevated aspartate transaminase 




























































Of the 15 patients, 10 were evaluable for response. A partial response was documented in 
two patients (20%) and stable disease was seen in five patients. One partial response was 
seen at level 1 and one at level 2A. 
 
4.4.4. Pharmacokinetic data 
The mean pharmacokinetic parameters for gemcitabine based on serial plasma 
concentration-time data from six patients at dose level 2A and one patient at level 2 are 
shown in Table 4.5. Plots of time against mean gemcitabine and dFdU concentrations at 
75 min and 90 min infusions of gemcitabine are shown in Figure 4.2. Plasma 
concentrations of gemcitabine were above 10 µM between 20 and 90 min in all patients. 
 
Table 4.5 Pharmacokinetic parameters of plasma dFdC.  













750 (n = 6) 315.4 ± 98.8 4.11 ± 1.20 4.79 ± 1.26 15.0 ± 3.5 76.0 ± 38.3 
900 (n = 1) 730.9 2.24 9.16 12.4 34.3 
Note: AUC: area under the concentration-time curve; Cl: clearance; Cmax: maxium 
concentration; T1/2: half-life; Vss: volume steady state.  


















Figure 4.2 Plots of time vs mean gemcitabine and dFdU concentrations with 75-min 
and 90-min infusions of gemcitabine (10 mg/m2/min). The horizontal line represents 
the gemcitabine plasma concentration of 10 µmol/L (2630 ng/ml). The plots for the 
75-min infusion represent the mean concentration values (n = 6) at each time point. 
The data for 90-min is from one patient (●gemcitabine, 75-min infusion; ○dFdU, 75-














In this study, we determined that the MTD for fixed dose rate infusion of gemcitabine at 
10 mg/m2 per min was 900 mg/m2 when given in combination with carboplatin at a 
targeted AUC of 5 mg/mL×min. The dose-limiting toxicities encountered included 
thrombocytopenia, neutropenia and liver dysfunction. 
The 750 mg/m2 dose of gemcitabine was found to be tolerable based on the occurrence of 
DLT in one out of six patients, in whom there was failure to recover from neutropenia for 
retreatment in the first cycle. As observed in previous study, [86] there was increased and 
cumulative hematopoietic toxicity with prolonged infusion. Hepatotoxicity had also been 
reported to be more frequent with longer infusions of gemcitabine [141] and was reflected 
by the frequency of elevated transaminases in our study patients, but this resulted in DLT 
in only one patient. 
For any chemotherapy combination to be feasible, recommended dosing should allow 
maintenance of relative dose intensity with repeated dosing without dose delay due to 
cumulative toxicity. In our study, there was an increase in hematopoietic toxicity with 
repeated dosing, but the relative dose intensity was still an acceptable 85% and three out 
of six patients at the recommended phase II dose completed six cycles of treatment. 
Although the recommended phase II dose of gemcitabine in our study was 750 mg/m2, it 
appeared that by infusing gemcitabine at 10 mg/m2 per min, hematological toxicities 
especially neutropenia, were similar to regimens using 30-min administration of 
gemcitabine at 1000 mg/m2 higher doses.  
The pharmacokinetics showed that gemcitabine plasma concentrations relevant for 
optimizing intracellular phosphorylated gemcitabine were achieved in most patients after 
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10 min of infusion. Clearance of gemcitabine was rapid, with a mean terminal half-life of 
15 min. The patient with DLT from neutropenia at 75 min infusion did not have the 
highest AUC of plasma gemcitabine. This is expected of antimetabolites like 
gemcitabine, where intracellular active metabolites reflect better clinically observed 
pharmacodynamics. With constant rate infusion, it might be possible to increase the 
duration of exposure to pharmacologically relevant concentrations of active metabolites, 
resulting in better cytotoxicity. 
In our Phase I study, there were high frequencies of grade 3/4 neutropenia. Based on data 
analysis, the frequency of grade 3/4 neutropenia did not increase proportionally with 
dosage of gemcitabine (Table 4.6). On the contrary, the frequency of grade ¾ neutropenia 
showed an inverse correlation (Fig. 4.3). The possible reasons would be explored from 

















Table 4.6 Reverse effect of dosage of gemcitabine and frequencies of severe 
neutropenia (grade 3/4). (Numbers in parentheses are the percentage of course having 





            Figure 4.3 Correlation of toxicity rate (%) and dosage of gemcitabine 
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A relative new regimen of gemcitabine administered as a 75-min infusion at a constant 
rate of 10 mg/m2 per min in combination with carboplatin was found to be tolerable and 
active in Asian NSCLC patients in our Phase I trial. Pharmacokinetic studies 
demonstrated that the target plasma gemcitabine concentration above 10 µM was 
achieved from 20-90 min during the 75 min infusion of gemcitabine at the stated constant 
rate regimen.  
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5.1. Introduction 
Preclinical studies showed that intracellular dFdCTP accumulation is dependent on the 
total exposure time and rate of administration of gemcitabine in human cell lines and 
xenografts [142, 143]Hence, the efficacy and toxicity of gemcitabine are influenced by the 
dose and dosing schedule [144] The clinical benefits from fixed dose rate infusion of 
gemcitabine at 10 mg/m2/min have also been reported in a randomized phase II study for 
patients with pancreatic adenocarcinoma, where higher intracellular dFdCTP 
accumulation in peripheral blood mononuclear cells was achieved compared to the 
standard 30-min infusion .[16] Since there were evidences to support prolonged infusion 
schedule of gemcitabine resulting in favourable activity of gemcitabine and carboplatin 
combination in advanced NSCLC, [145] we conducted a randomized phase II study of 
gemcitabine in combination with carboplatin in patients with advanced NSCLC utilizing 
two different infusion rates of gemcitabine. The dose for fixed dose rate infusion of 
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5.2. Objectives of the study 
Our study aims were to analyze plasma and cellular pharmacokinetics of gemcitabine and 
its metabolites; to evaluate the response rate, overall survival and toxicity of carboplatin 
and gemcitabine given at a fixed rate infusion (arm A) and standard 30-minute infusion 
(arm B) and to correlate the pharmacokinetic parameters of gemcitabine and its 
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5.3. Methodology 
5.3. 1. Patient selection 
The Eligibility criteria included histologically or cytologically confirmed NSCLC with 
measurable disease, stage IIIB unsuitable for radical radiotherapy or stage IV disease. 
Patients were required to have a Karnofsky performance status (KPS) of ≥ 70%, age ≥ 18 
years, life expectancy > 3 months, hemoglobin ≥ 9g/dL, white blood cell count ≥ 
3500/µL, neutrophils ≥ 2000/µL, platelet count ≥ 100 000/µL, serum creatinine < 133 
µmol/L or creatinine clearance > 30 mL/min (based on the Cockcroft formula), serum 
bilirubin ≤1.5 times the upper limit of normal (ULN), and serum transaminase levels ≤ 
two times ULN or ≤ five times ULN if hepatic metastases were present. The study was 
approved by the institutional review board of each participating centre and all patients 
gave written informed consent. Previous chemotherapy for advanced disease was not 
allowed. Prior neoadjuvant or adjuvant chemotherapy or chemotherapy given with 
radiotherapy for non-metastatic disease was allowed if the last dose was administered ≥6 
months before study entry. Patients were excluded if they had received prior gemcitabine 
therapy or had symptomatic central nervous system metastases requiring steroids. Prior 
radiotherapy was allowed provided the indicator site(s) had not been irradiated and the 
last dose of radiation therapy had been completed ≥3 weeks before study entry. 
 
5.3.2. Treatment Plan 
Patients were randomly assigned to the following two treatment arms: gemcitabine 750 
mg/m2 over 75 min at a constant infusion rate (arm A) or gemcitabine 1000 mg/ m2 over 
30 min (arm B) on days 1 and 8 every 3 weeks. An infusion pump was used to ensure 
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exact infusion time. In both arms, carboplatin targeting AUC of 5 mg/ml×min was given 
over 1 h on day 1 prior to the gemcitabine infusion. Stratified randomization was 
performed using the minimization method based on study site, KPS (90–100% versus 
70–80%), and disease stage (IIIB versus IV). Dose modifications were based on weekly 
blood counts and toxicity. On day 22 of each cycle, for grade ≥ 1 neutropaenia and/or 
platelets < 100 000/ µL, treatment was delayed for 1 week. On day 8 of each cycle, for 
grade 3 neutropaenia and grade 2 thrombocytopaenia, the dose of gemcitabine was 
reduced by 25% and maintained for the next cycle, and for grade 4 neutropaenia and/or 
grade 3/4 thrombocytopaenia, gemcitabine was omitted and decreased by 25% for the 
next cycle following marrow recovery and carboplatin was also reduced by 10% the next 
cycle. Gemcitabine was also reduced by 25% and carboplatin by 10% for a grade 4 
neutropenic fever or grade 4 neutropaenia for > 7 days or thrombocytopaenia grade ≥ 3 
with bleeding or platelets <25000/µL. Patients requiring a third dose reduction, or 
experienced a nonhaematologic toxicity of > 3 (except for nausea, fatigue, or reversible 
elevation of transaminases) were taken off study. 
 
5.3.3. Patient Evaluation 
Prior to chemotherapy, patients underwent a history and physical examination, chest X-
ray, chest and abdominal computed tomography (CT) scans, complete blood count 
(CBC), serum biochemistry, urinalysis, and ECG. Additional radiological imaging was 
performed if clinically indicated. A physical examination, recording of toxicities, serum 
biochemistry was performed prior to each cycle of therapy. Weekly CBC was obtained 
during each cycle. 
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5.3.4. Early Phase Tumor Response  
Tumor response was evaluated after every two cycles. Patients with stable disease or 
better continued with treatment to a maximum of six cycles. Confirmed responses 
required repeat CT scans at least 4 weeks later. Early detection of tumor shrinkage could 
provide a valuable marker for oncologists to decide whether to switch patient’s treatment 
at the early phase of chemotherapy. 
We used tumor shrinkage data from first two cycles mainly because on the one hand, 
there was usually a delay time for tumor response and there would be few cases to 
observe significant dimension changes of tumors in the first cycle of chemotherapy. 
Hence, tumor response would not be evaluated after the first cycle. On the other hand, it 
would be too late to switch chemotherapy treatment for many patients if oncologists got 
the information on the tumor shrinkage after routine six cycles of chemotherapy. In order 
to fill this gap, we associated the plasma concentration ratios of metabolite/gemcitabine 
with early phase tumor shrinkage data to identify potential disease progression markers 
for gemcitabine-based chemotherapy. Tumor response was assessed according to 
standard RECIST criteria (Table 5.1)  
Table 5.1 RECIST response criteria for evaluation of target lesions 
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If the value is less than 30 %, the case was taken as non-responders including PD and SD. 
The others (equal or bigger than 30 %) were regarded as responders including CR and PR 
according to RECIST criteria. [140] 
 
5.3.5. Pharmacokinetic Analysis 
This study plan was to determine the relationships between pharmacodynamic measures 
(hematologic toxicity, tumour shrinkage), against the plasma pharmacokinetics of 
gemcitabine, and cellular pharmacokinetics of gemcitabine using peripheral mononuclear 
cells. The pharmacokinetic information obtained will enable correlative study with the 
clinical endpoints like toxicity and efficacy. We studied gemcitabine and dFdU 
concentrations in the plasma, as well as the concentrations of dFdCTP in the peripheral 
mononuclear cells. All pharmacokinetic sampling was done in the first cycle of treatment. 
 
5.3.5.1. Plasma dFdC and dFdU concentrations 
Ten millilitres of blood were drawn at 0 hours (baseline), 10 minutes, 30 minutes, 10 
minutes before the end of the infusion, and 30 minutes, 1 hour, 2 hours after the end of 
the infusion. The blood was drawn into 10 ml tubes (green topped) containing heparin 
and 5 μmol tetrahydrouridine. The tubes were then centrifuged at 3300 rpm for 15 
minutes and the supernatant plasma was transferred to cryo tubes for immediate storage 
at –80 oC. Samples were labelled with the patient’s study number, dosage and sampling 
times and protocol number (Table 5.2). A pharmacokinetic form would accompany the 
plasma samples for pharmacokinetic analysis. 
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Gemcitabine and dFdU concentraions in plasma were measured using LC-MSMS method 
described in chapter two, section 2.3.3.1. Briefly, to a 1.5 ml Eppendorf tube was added 
50 μl of plasma samples or calibrators, 5 μl of 50 μg/ml aqueous solution of 
Gemcitabine-13C, 5N2 (internal standard), and 200 μl of acetonitrile. The tube was 
tightly capped and immediately vortex-mixed for 1 minute, and then centrifuged at 
10,000×g for six minutes at 4 °C. One hundred μl of supernatant was transferred into 
another Eppendorf tube and dried under nitrogen and reconstituted with 50 μl of 10 mM 
ammonia acetate buffer solution pH 6.8. After mixing, 40 μl of the mixture was 
transferred to plastic insert for LC-MSMS analysis.  
 
5.3.5.2. Intracellular dFdCTP levels 
Samples of blood from first cycle were collected to assay intracellular dFdCTP. Five 
samples per patient, obtained 10 min, 30 min, 10 min before completion of infusion, and 
30 min, 1 h, and 2 h after completion of the infusion, were assayed for dFdCTP.  
Plasma was first separated from the blood by centrifugation at 3300 rpm for 20 minutes. 
Mononuclear cells were then isolated by Ficoll-Hypaque density gradient centrifugation 
and deoxyribonucleoside triphosphates were extracted with 0.4 N HClO4, and the acid-
insoluble material was removed by centrifugation. The supernatant was then carefully 
neutralised with potassium hydroxide and kept on ice for 20 min for KClO4 precipitation. 
The precipitate was then removed by centrifugation. An ion-exchange high performance 
liquid chromatography method was then used to separate and quantitate the dFdCTP as 
described in chapter two, section 2.3.3.2. 
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5.3.5.3. Pharmacokinetic calculation 
Noncompartmental analysis was performed using WinNonlin 5.2. (Pharsight 
Corporation) to calculate the pharmacokinetic parameters, clearance (CL), half-life of the 
terminal disposition phase (t½), and volume of distribution at steady state (Vss) for 
gemcitabine and dFdCTP. Area under the concentration-time curve (AUC) was estimated 
using the log-linear trapezoidal option from time 0 to infinity. Derivation of the rate 
constant for the terminal phase, k, was done with the final three sampling time points and 
extrapolation of the last measured concentration to infinity. Clearance (CL), half-life (t½) 
and steady state volume of distribution (Vss) were computed.  
In addition, compartmental analysis was also used to fit and simulate the plasma 
gemcitabine concentrations through changing the infusion time. According to time-
concentration curve visualization and AIC criteria, two compartment modelling (model 
10) was adopted to calculate modeling pharmacokinetic parameters of dFdC 
concentrations and good fitting was achieved using a 1/Y weighting model. After that, 
simulation was processed according to the calculated pharmacokinetic parameters for 
different infusion time to evaluate the effect of infusion time on blood concentrations of 
dFdC.  
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5.3.6. Statistics 
Pharmacokinetic data between the two treatment arms and between male and female 
within same treatment schedules were compared using the Student’s t-test. The t-test was 
analyzed as two tailed distribution and two-sample unequal variance. The sample size 
was calculated based on the statistical selection theory. Assuming a 90% probability of 
correctly choosing the best treatment, and anticipating a baseline response rate of 40%, to 
detect a 15% superiority of the best treatment, a sample size of 37 patients per treatment 
arm was needed.  
Efficacy parameters were evaluated according to intent-to-treat (ITT) analysis. Survival 
and TTP (time to progression, were measured as the time from randomization until death, 
disease progression or last contact) were calculated using the Kaplan-Meier technique. 
Survival was calculated from the date of randomization to the date of death or last follow 
up. TTP was defined as the time from randomization until disease progression, or last 
contact. The difference between the two treatment groups was tested by log-rank test. 
In the phenotypic study, the difference in plasma concentration ratio of 
dFdU:gemcitabine between responders and non-responders was tested by Mann Whitney 
test. The frequency difference of the ratio larger than 500 distributed in responders and 
non-responders was tested by Chi Square test.  
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5.3.7. Hematological toxicity modeling 
Toxicities were evaluated every cycle using the National Cancer Institute Common 
Toxicity Criteria, version 2.0.  
Dependent variables included absolute Neutrophil Count Nadir (ANCnadir) for 1st cycle 
(ANCnadir_c1) and over all cycles (ANCnadir_all) and Platelet Count Nadir (PLTnadir) 
for 1st cycle (PLTnadir_c1) and over all cycles (PLTnadir_all). The natural logarithm 
transformation of the nadir neutrophil and nadir platelet values was used as a dependent 
variable for exploring pharmacodynamic relationships. The reason for this lies in the 
possible existence of polynomial relationships (powers of the predictor variables) 
between the predictor variables and the dependent variable [59] Separate Linear regression 
analysis was used to relate ANCnadir_c1, lnANCnadir_c1, ANCnadir_all, 
lnANCnadir_all, PLTnadir_c1, lnPLTnadir_c1, PLTnadir_all, and lnPLTnadir_all to the 
independent variables. Independent pharmacokinetic variables thought to affect 
hematological toxicity were considered for this correlation analysis, including dFdC 
exposure assessed by the first dose, AUC or body surface area normalized AUC, CL and 
duration of exposure of dFdC above 5 or 10 µM as well as intracellular dFdCTP exposure 
assessed by AUC and body surface area normalized AUC.  
Since our patients were assigned into two cohorts, 30 min infusion group and 75 min 
infusion group, a within group toxicity association analysis was used to exclude the 
confounding factor caused by different infusion schedules. All the linear regressions were 
performed using SPSS Version 13.0 through stepwise approach.   
Chi-square test was used to compare severe hematologic toxicities in arm A and arm B.  
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5.4. Results  
5.4.1. Patient characteristics 
Between July 2001 to February 2004, 76 patients were accrued from Singapore and 
Australia (Table 5.3). The study was approved by the institutional review board of each 
participating centre and all patients gave written informed consent. One patient withdrew 
consent after randomization and did not receive treatment. 
 
 
Table 5.3 Patient characteristics 
Treatment Arm A (n = 38) 
Fixed dose rate 
Arm B ( n = 37) 
Standard infusion 
Age (years)   
Median 55 62 
Range 39-77 32-76 
Sex   
Male 24 29 
Female 14 9 
Disease Stage   
IIIB 7 7 
IV 31 31 
KPS status (%)   
90-100 31 31 
70-80 7 7 
Histology   
Adenocarcinoma 19 26 
Squamous cell 5 4 
Large cell 4 4 
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5.4.2. Treatment  
A total of 322 cycles of chemotherapy was administered (150 in arm A and 172 in arm B) 
with a median number of four cycles (range 0 to 6). In arm A, gemcitabine was omitted 
in 3.7% and reduced in 21.3% of courses. In arm B, 2% and 15.7% of gemcitabine doses 
were omitted or reduced respectively. In both treatment arms, the most common reasons 
for dose omission and reduction were neutropaenia and thrombocytopaenia. Carboplatin 
was reduced in 18.7% of doses in arm A and 12.8% in arm B. The relative dose intensity 
(RDI, the dose intensity that was delivered compared with the intended dose intensity) of 
gemcitabine was 83% and 84% in arms A and B respectively. [146] RDI has been taken as 
an important prognostic factor for survival in diffuse large cell lymphoma treated with 
multidrug regimens. [147] 
 
5.4.3. Toxicity 
Seventy-five patients were assessed for toxicity (Arm A, n = 38, Arm B, n = 37). Grade 
3/4 anaemia and neutropaenia was similar in both treatment arms (Table 5.4) whilst grade 
3/4 thrombocytopaenia was more frequent in arm A (69% versus 50%), this, however, 
was not statistically significant with Pearson Chi-square test (p = 0.10). Two episodes of 
neutropaenic fever were reported, one in each treatment arm. Significant non-
hematological toxicities were infrequent and tolerable in both treatment arms (Table 5.5). 
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Table 5.4 Hematological toxicities (% of patients) 
 Arm A Arm B p-value 
Toxicity Grade 3/4 Grade 3/4  
Anaemia 31 33 1 
Neutropaenia 68 75 0.61 




Table 5.5 Non-hematological toxicities for grade 3 or 4 (% of patients) 
Toxicity Arm A Arm B 
 Grade 3 Grade 4 Grade 3 Grade 4 
Anorexia 3 0 3 0 
Nausea 5 0 0 3 
Vomiting 5 0 0 0 
Diarrhoea 0 3 0 0 
Constipation 3 0 3 0 
Fatigue 8 3 5 0 
Rash 5 0 13 0 
ALT 0 0 3 0 
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5.4.4. Efficacy 
5.4.4.1. Response Rate and Survival 
Five patients (three in arm A, two in arm B) did not undergo tumor assessment because 
of early disease progression (three patients), lost to follow-up (one patient) and 
withdrawal of consent (one patient). All patients were included in the response 
assessment as per ITT (Intent-to-Treat) analysis. No patient had a complete response. 
Thirteen patients (34%, 95% CI 26–59%) in the fixed dose rate arm and sixteen patients 
(42%, 95% CI 20–51%) in the 30-minute arm had partial responses. The median follow 
up was 233 days. The median TTP (Time to Progression) was 160 days (95% CI 96–210 
days) in arm A and 157 days (95% CI 116–214 days) in arm B (Figure 5.1). No 
significant difference was seen between the two treatment groups (p = 0.73, log-rank test 
HR 1.08, 95% CI 0.68–1.73) The median survival and one year survival rate was 212 
days (95% CI 176–263 days) and 31.6% respectively for patients in arm A and 287 days 
(95% CI 191–394 days) and 35.6% respectively for patients in arm B. 
 
Figure 5.1 Progression free survival 
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5.4.4.2. Early Phase Tumor Response  
The tumor was measured at day 1 before gemcitabine chemotherapy and first two cycles 
later. The tumor shrinkage percentage was calculated according to following formula 1: 
Percentage Shrinkage (%) = (Diameterday1- Diameterday42)/Diameterday1×100          … (1) 
In consideration of slight check time difference on tumor size measurement due to 
logistic or physical reasons, we set an acceptable range for this tumor measurement time 
after first two cycles as day 42 ± 7. There were 58 subjects were from Singapore. Among 
them, five patients (three in arm A, two in arm B) did not undergo tumor assessment 
because of early disease progression (three patients), lost to follow-up (one patient) and 
withdrawal of consent (one patient). Among 53 patients left, four patients were 
withdrawn after 1st cycle of gemcitabine in combination with carboplatin from the study 
due to disease progression. Thirteen subjects were found to have shrinkage percentage 
≥30 and these were considered as responders while there were 36 non-responders with 
shrinkage percentage <30.  
 
5.4.5. Pharmacokinetic data 
5.4.5.1. Non-compartmental Anaysis 
Plasma gemcitabine were analyzed in 58 patients using non-compartmental analysis (29 
in each arm, all from Singapore) and intracellular dFdCTP was determined in 33 patients 
(arm A 15 patients, arm B 18 patients). Peak plasma gemcitabine concentrations occurred 
earlier in arm B than in arm A (Table 5.6A). In arm A, Cmax of gemcitabine was 20.8 ± 
17.2 µM at 51 min compared to 41.2 ± 13.9 µM at 29 min in arm B (Table 5.6B). Mean 
gemcitabine AUC was 1345.9 ± 1112.6 µM×min and 1432.4 ± 528.9 µM×min in arm A 
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and B, respectively. Terminal elimination was similar, with a mean clearance of 164.0 ± 
64.0 l/h/m2 in arm A and 181.6 ± 74.5 l/h/m2 in arm B (Table 5.6A). The volume of 
distribution of gemcitabine was 65.0 ± 37.2 L in arm A and 74.5 ± 41.2 L in arm B, 




Table 5.6 Pharmacokinetic parameters of (A) plasma gemcitabine and (B) 
intracellular gemcitabine triphosphate. Values are expressed as mean ± SD, 
Cmax maximum concentration, Tmax time to maximum concentration, AUC 
area under the concentration time curve, Vss volume of distribution at steady 
state, CL clearance. 
A: Plasma gemcitabine pharmacokinetic parameters 
 Arm A (n = 29) Arm B (n = 29) 
Dose gemcitabine (mg) 1193 ± 145.3 1600 ± 197.5 
Cmax (µM) 20.8 ± 17.2 41.2 ± 13.9 
Tmax (min) 51.3 ± 17.2 28.8 ± 8.6 
AUC0-inf (µM*min) 1,345.9 ± 1112.6 1,432.4 ± 528.9 
AUC extra (%) 0.3 ± 0.3 0.3 ± 0.3 
Vss (L) 65.0 ± 37.2 74.5 ± 41.2 
CL (L/h) 261.8 ± 106.7 293.0 ± 128.1 
CL (L/h/m2) 164.0 ± 64.0 181.6 ± 74.5 
t1/2 (min) 18.2 ± 4.2 17.1 ± 3.1 
 
B: Intracellular gemcitabine triphosphate pharmacokinetic parameters 
 Arm A (n = 29) Arm B (n = 29) 
Cmax (µM) 173.9 ± 77.3 224.8 ± 73.8 
Tmax (min) 1.6 ± 0.4 0.9 ± 0.2 
Apparent AUC0-inf (µM*min) 35079 ± 18216 32249 ± 11267 
AUC extra (%) 32 ± 7 28 ± 5 
Apparent CL (L/h) 8.6 ± 3.4 11.0 ± 4.1 
Apparent CL (L/h/m2) 5.2 ± 2.0 7.0 ± 2.6 
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The pharmacokinetic profiles of dFdC and the inactive dFdU were shown in Figure 5.2 
and that of intracellular dFdCTP accumulation was shown in Figure 5.3. Higher 
intracellular dFdCTP accumulation was observed in Arm B but was unlikely to be at 
saturation point according to our previous in vitro results (Chapter three), showing that 
the incubation time is the determinant of intracellular dFdCTP accumulation and 
retention. The saturation of intracellular dFdCTP was only achieved after 8 h incubation 
when applied concentration of dFdC was ≥ 10 µM. In contrast, our clinical infusion time 
was one seventh of the exposure time of in our in vitro experiment. 
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Thus, the increase of infusion time from 30 min to 75 min might enhance the intracellular 
accumulation of dFdCTP, but its contributory effect could be compromised by the dose 
reduction (1000 mg/m2 in 30-min arm vs 750 mg/m2 in 75-min arm). Intracellular 
dFdCTP AUC was similar at 35 079 ±18 216 µM×min and 32 249 ± 11 267 µM×min in 
arms A and B (p = 0.08, t-test), respectively (Table 5.6B). Their pharmacokinetic profiles 
were shown in Figure 5.3. 
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Figure 5.7 showed the plasma concentration ratios of dFdU/gemcitabine with time. Since 
gemcitabine was metabolized very fast in plasma, its plasma concentration would 
decrease quickly after stopping infusion. Thus, the range of the plasma concentration 
ratios of dFdU/gemcitabine increased quickly with increase of sampling time after 
infusion.    
  
Table 5.7 Plasma concentration ratio of dFdU/gemcitabine in NSCLC patients 
 
Sampling    
Time Subjects Range Minimum Maximum Mean 
10 min 48 2.07 .06 2.13 .7475 
30 min 51 13.71 .95 14.66 2.5090 
(-)10 min 52 4.29 .79 5.08 2.2357 
(+) 30 min 52 123.58 4.25 127.83 27.7444 
(+) 60 min 50 403.78 7.76 411.54 94.0594 




5.4.5.2. Compartmental Analysis on Gemcitabine Plasma Concentration 
Most previous studies report plasma pharmacokinetic parameters of gemcitabine using 
non-compartmental analysis (NCA). This is due to the limitation of gemcitabine 
determination sensitivity, especially in elimination phase where the concentrations are 
very low. The disadvantage of NCA is that the data obtained are not useful for 
simulations of different infusion rates before initializing new clinical trials. Recent 
development in LC-MSMS applications has resulted in enhanced sensitivity. We utilized 
compartmental modeling to fit our data. In our model selection exercises, one and two 
compartment models with or without weighting were compared. Three compartment 
models could not be tested due to the limitation of sampling points. According to the 
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results of concentration-time profile visualization and minimized Akaike Information 
Criterion (AIC), a two-compartment model (model 10) with 1/Y weighting provided the 
better fitting model and was used for the plasma concentrations of gemcitabine. The 
pharmacokinetic parameters for two treatment schedules were listed in Table 5.8. The 
dose of gemcitabine applied in arm A is 30 % less than that in arm B. The differences in 
AUC were in the same magnitude as their doses. The clearances and Vss in both arms 
were similar. Maximum concentrations in arm B were significant higher than those in 
arm A. AIC criteria from 1/Y weighting model was much lower than those without 





    
Table 5.8 Difference of Pharmacokinetic parameters of plasma gemcitabine 
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5.4.6. Hematological models 
Although seventy-six patients were accrued in this study, fifty-eight patients with plasma 
pharmacokinetic data of gemcitabine and dFdU were available for analysis. Among them, 
thirty-three patients with dFdCTP intracellular concentrations were available for 
hematologic toxicity association analysis with dFdCTP exposure. Initially, we analyzed 
the pooled data from both arms. No relationship was found between neutrophil nadir 
/platelet nadir and gemcitabine pharmacokinetic parameters or dose. Hence, an individual 
correlation analysis was carried in individual arm. Among the parameters tested, only 
AUC of dFdCTP in arm B was identified to have a modest linear relationship with natural 
log neutrophil nadir (r = -0.51) (Table 5.9) and was also found to be associated with in 
natural log platelet nadir (r= -0.692) (Table 5.10, Figure 5.4). However, arm A did not 
show such relationship. 
 
 




r intercept β p value F value 
CldFdC -0.095 6.528 -0.030 0.722 0.131 
CldFdC_BSA -0.232 6.793 -0.129 0.371 0.850 
AUCdFdC 0.265 5.802 0.000 0.304 1.132 
AUCdFdC_BSA 0.095 6.171 0.000 0.712 0.142 
AUCdFdCTP -0.365 7.110 -0.000023 0.151 2.295 
AUCdFdCTP_BSA -0.515 7.110 -0.000048 0.034 5.415 
 








r intercept β p value F value 
CldFdC -0.263 4.226 -0.124 0.309 1.110 
CldFdC_BSA -0.263 4.226 -0.124 0.309 1.110 
AUCdFdC 0.212 3.439 0.000 0.412 0.711 
AUCdFdC_BSA 0.155 3.548 0.000 0.549 0.375 
AUCdFdCTP -0.698 5.015 -0.000038 0.002 14.256 




Figure 5.4 Association of thrombocytopenia with dFdCTP exposure for arm B 
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5.4.7. Correlation of dFdU/gemcitabine ratios with demography & tumor shrinkage 
To investigate whether there is any correlation between metabolite/parent ratios and 
demography as well as response, the dFdU/gemcitabine ratios were computed for each of 
sampling times (Table 5.7). Pearson correlation and t test showed no correlation and 
effect of demography on the concentation ratios of dFdU/gemcitabine (Table 5.11).  
 
 
Table 5.11 Effect of demographic factors on plasma concentration ratio of dFdU 





When the metabolite/parent ratios at the different sampling times were statistically tested 
(Mann-Whitney U test) with early phase tumor response (section 5.4.4.2), it was found 
that the ratios at 120 min were significantly different (Table 5.12 and Fig. 5.5). The ratios 
of the responders were much smaller than those of the non-responders.  
 
 





Table 5.12 Relationship between responders and plasma concentration ratio of 
dFdU versus gemcitabine 







Mann-Whitney U 193.500 201.000 181.500 233.000 197.000 125.000 
Wilcoxon W 298.500 306.000 286.500 338.000 302.000 216.000 
Z -1.831 -1.102 -1.636 -.549 -1.062 -2.555 
Asymp. Sig.  
(2-tailed) .067 .270 .102 .583 .288 .011 





Figure 5.5 Box plot of response vs concentration ratios of dFdU and gemcitabine  
  at 120 min after infusion 




In order to predict the responders or non-responders, a frequency histogram was drawn 
according to concentration ratios of dFdU/gemcitabine at 120 min (Fig. 5.6).  
 
 
Figure 5.6 Frequency histogram for the concentration ratios of dFdU/gemcitabine at 




The ratios of dFdU/gemcitabine were widely distributed in the range of 106 to 1256. The 
middle value with 575 was labeled as a red line in Figure 5.6. This line possessed a 
different meaning for each group. For non-responders, this line nearly separated this 
group equally. It could not be used as a marker to identify non-responders from the study 
cohort. However, there was a different situation for responders. Among 13 responders, 
only one subject (7.69%) had the ratio of dFdU/gemcitabine bigger than 575. This result 
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indicated that in general responders to gemcitabine treatment were most likely to have 
low dFdU/gemcitabine ratios. This result also suggested that gemcitabine’s deamination 
rate could be a determinant factor in chemotherapeutic activity where a larger ratio 
represents faster deamination rate.  
Through Figure 5.6, the red line could distinguish non-responders from the all subjects. 
When the ratio was larger than 575, there would be 94% (16 out of 17) probability to 
predict this subject as a non-responder. In addition, a ratio of 500 would be a better cutoff 
value to predict non-responders. In this case, the probability to predict non-responders 
was increased nearly to 95% (18 out of 19). 
Hence, the cutoff ratio was set as 500, subjects with ratios < 500, would be slow 
deaminators, while those with ratios ≥ 500, would be fast deaminators. In the responders, 
only one in thirteen (7.69%) had a value >500. On the contrary, there was a much higher 
percentage (50%, 18 over 36) with >500 in non-responders. This difference was 
statistically significant Chi Square test (p = 0.004). This finding provided an important 
marker in evaluating the efficacy of gemcitabine at an early phase (2nd cycle) of 
gemcitabine chemotherapy. For example, if the ratio is ≥ 500, it might imply that the 
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5.5. Discussion 
This randomized phase II study compared the pharmacokinetics of plasma gemcitabine 
and intracellular dFdCTP in a large set of patients receiving gemcitabine either as a fixed 
dose rate or as a standard infusion rate in combination with carboplatin. In addition, 
pharmacodynamics and toxicities were also compared between the two arms. Early phase 
response was evaluated and a potential progression marker was explored to predict non-
responders to gemcitabine combination therapy with carboplatin in NSCLS patients.  
 
5.5.1. Phase II pharmacokinetic study of gemcitabine dosing 10 mg/m2/min for 75 
min or 1000 mg/m2 for 30 min 
One of main objects of this study was to evaluate the pharmacokinetics of plasma 
gemcitabine and intracellular dFdCTP between the two treatment arms. According to 
Table 5.6, although both AUC0-inf and CL in arm A were 89% of those in arm B, these 
differences were not statistically significant (p = 0.38 for AUC0-inf and p = 0.32 for CL). 
However, the mean exposure time above 10 µM (Figure 5.2) was 80 min and 50 min for 
arm A and arm B, respectively. This suggested that fixed rate infusion might be more 
efficient than standard 30 min infusion.  
On the other hand, the AUC0-inf of intracellular dFdCTP was similar in both treatment 
arms despite the dose of gemcitabine being 25% higher in arm B. Consistent with 
previously reported studies, [18, 46, 148] the pharmacokinetic data demonstrated that the 30-
min infusion arm was a pharmacologically less efficient method of administering 
gemcitabine compared to a fixed dose rate of 10 mg/m2/min. In arm B, a higher mean 
plasma gemcitabine Cmax of 41.2 uM was reached, a value that was well outside the 
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concentration range known to optimize the rate of gemcitabine phosphorylation.  
 
5.5.2. Phase II pharmacodynamics and toxicities of gemcitabine dosing 10 
mg/m2/min for 75 min or 1000 mg/m2 for 30 min 
The response rates in both study arms were consistent with the established efficacy of this 
regimen in NSCLC. Similar outcome measures of response rates, time to disease 
progression, survival and toxicities were found using carboplatin with gemcitabine at 750 
mg/m2 in a 75-min infusion or at 1000 mg/m2 in a 30-min infusion in the treatment of 
advanced NSCLC. Response rates were reported to range from 29% to 42% in studies 
using carboplatin and 30-min infusion gemcitabine [97, 121, 149] and 34% to 47% in studies 
of gemcitabine administered at 10 mg/m2/min with carboplatin or cisplatin. [17, 150] Whilst 
significant myelosuppression was seen in both treatment arms, the frequency of 
neutropaenic fever and bleeding from thrombocytopaenia was low. The relative-dose 
intensity (RDI, a scientific term refers to the amount of a particular chemotherapy given 
over a specific time in relation to what was originally ordered) of gemcitabine in arm A of 
83% was similar to that in arm B (84%) and compared favorably with the 75% for 
gemcitabine reported in a phase II study of carboplatin and gemcitabine 1200 mg over 
120 min in NSCLC. [151] Therefore, a fixed dose rate infusion of gemcitabine with 
carboplatin was feasible without major cumulative toxicities. Previous studies using a 
prolonged gemcitabine infusion schedule reported elevation in hepatic transaminases; [12] 
this, however, was not seen in our study and could be related to duration of the infusion.  
As phosphorylation of gemcitabine was more efficient in the fixed dose rate arm, a lower 
dose of gemcitabine could be administered, with the resultant benefit of reduced 
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chemotherapy costs. This advantage, however, might be offset by increased charges 
associated with a longer infusion time and nursing costs as well as greater inconvenience.  
Regarding to hematological toxicity modeling, logarithm transformation of the nadir 
neutrophil counts and platelet counts was used as dependent variables due to following 
two reasons. One of our assumptions was based on logarithmic transformation of the 
equation:  
SF = e[-k×AUC] which yields a linear relationship, e.g.  
ln (nadir/platelet counts) = ln (pretreatment count)-k×AUC, where SF is the survival 
fraction of cells and k is the rate constant that determines the slope of the decay curve, 
AUC is the area under the curve of the antineoplastic agent under study, and ln is the 
natural logarithm. The other reason was that we assumed that the logarithm 
transformation of neutrophil/platelet nadir counts could result in a better normalization 
which made the data more predictable. [59]  
Our results showed that AUC of dFdCTP correlated with hematological toxicity like 
thrombocytopenia only in arm B (Fig 5.4). The possible reason might be that gemcitabine 
is a highly hydrophilic compound and enters the cell through active human nucleotide 
transportation. When infusion rate (e.g. 75 minute infusion) was low, gemcitabine might 
be more efficiently transported into the cells. The percentage of drug remaining in blood 
circulation system would be low. However, when the infusion rate (e.g. 30 minute 
infusion) was high, potential saturation on human nucleoside transporters could result in 
a greater percentage of gemcitabine in blood circulation system during infusion. Different 
concentrations of gemcitabine in blood circulation system might produce a different 
dFdCTP accumulation velocity in the white blood cells. According to Michaelis_Menten 
Chapter V. PK & PD of Gemcitabine at Two Infusion Rates 
 135
equation, the velocity of dCK would highly depend on the concentration of gemcitabine, 
the substrate of dCK. If the peak concentrations of gemcitabine were at about 10 µM in 
case of 75 min infusion, the enzyme velocity would vary sharply since the concentration 
of substrate was the same magnitude as Km (Km was reported as being in the range of 5-
10 µM).[152, 153]  If the peak gemcitabine concentrations were at relatively high value in 
case of 30 min standard infusion (33 mg/m2 per minute), the enzyme velocity would 
approach maximum value at the plateau phase to saturate dCK. [154] Only in this situation, 
the formation rate of dFdCTP could reach its maximal value and the resultant values from 
different subjects could represent their dCK activities. Thus, the differences among 
individuals in toxicities could be differentiated. Hence, only for arm B, the difference of 
dFdCTP accumulation between individuals could be compared each other since their 
enzyme velocities were at the ceiling status and dFdCTP accumulation was highly 
dependent on enzyme’s activity for each patient. Therefore, this would account for the 
fact that there was a good correlation between dFdCTP exposure and myelosuppression, 
especially for thrombocytopenia only in arm B. If we analyzed all the subjects from two 
arms, the data from arm A (75 min infusion) would become a confounding factor. Thus, 
we could not find any correlation in the combined dataset. 
 
5.5.3. Early phase progression marker for non-responders to gemcitabine treatment 
in NSCLC 
Individualization of chemotherapy for cancer patients is currently becoming more and 
more important in minimizing adverse effects without compromising efficacy. However, 
the biggest challenge is to identify and validate sensitive and specific markers for each 
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cancer treatment. One of the most important markers is early phase tumor shrinkage 
maker which is useful for oncologists to evaluate the therapeutic efficacy so as to decide 
if alternative agents should be sorted for non-responders to current treatment instead.  
The effect of chemotherapeutic agents on solid tumors is most commonly categorized and 
reported based on the RECIST. This classification divides both target and non-target 
lesions’ response into four categories-complete response (CR), partial response (PR), 
progressive disease (PD) and stable disease (SD) in all treatment cycles. It offers a simple 
criterion that standardizes the measurement and interpretation of tumor responses across 
clinical trials, allowing cross comparison between trials and anticancer drugs. However, 
this all cycle based evaluation assay may finally result in a treatment failure for non-
responders who could miss the best opportunities for other anti-cancer drugs in early 
treatment phase. Hence, early detection of non-responders is a big challenge in achieving 
higher successful chemotherapeutic rates. In our study, a novel tumor shrinkage marker 
(ratio of dFdU:gemcitabine at the 120 min sample point) was identified to predict non-
responders to gemcitabine treatment in NSCLC with as high as 95% prediction 
probability. Furthermore, no difference on demographic parameters was detected between 
responders and non-responders (section 5.4.7). In addition, there was no significant 
difference on the ratios of metabolite/parent for other sampling times except for 120 min. 
Responders generally had a smaller the ratio of dFdU/gemcitabine at 120 min. With a 
cutoff value of 500, the ratio of dFdU/gemcitabine at 120 min could be used to predict 
non-responders to gemcitabine treatment combined with carboplatin in NSCLC. As long 
as this marker could be validated with larger datasets in clinical setting, it would be easily 
accessible and useful in evaluating tumor progression in the early phase.  
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5.6. Conclusions 
Based on our pharmacokinetic study,  by using a 25% lower dose of gemcitabine at an 
infusion rate of 10 mg/m2/min in combination with carboplatin in NSCLC, an equivalent 
clinical efficacy and safety profile was achieved compared to standard 30-min infusion 
regimen. In addition, our pharmacokinetic-pharmacodynamic association analysis 
showed that intracellular dFdCTP exposure could be a potential tool to predict 
thrombocytopenia due to gemcitabine based chemotherapy in 30 min infusion regimen. 
Due to the difficulty in measuring intracellular dFdCTP, other convenient surrogate 
markers in pharmacokinetics and pharmacogenetics should be further explored in order to 
better predict the efficacy of chemotherapy by optimizing individualized treatment. 
Moreover, our results showed that the early phase (after 2nd cycle) tumor shrinkage was 
highly related to plasma concentration ratio of dFdU/gemcitabine (metabolite:parent). 
The average ratio of non-responders at the 120 min sample point was significantly (p = 
0.011; Mann Whitney test) higher than that of the responders. However, this surrogate 
marker is not correlated to patient survival time, one of the most important endpoints. A 
large prospective clinical trial would be designed to further validate our finding that the 
ratio of dFdU/gemcitabine is a good and valuable marker to predict non-responders in 
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6.1. Introduction 
Gemcitabine displays a good anticancer effect profile on many types of cancers, 
especially for solid tumors due to its special mechanisms of action. Although it possesses 
a minor difference of chemical structure compared to that of cytarabine, gemcitabine 
shows a superior anticancer activity through its active phosphorylated metabolites 
(gemcitabine diphosphate and triphosphate) after it enters the cells. This may be 
attributed to high accumulation and slow elimination of gemcitabine triphosphates which 
inhibits processes required for DNA synthesis and RRM. According to the previous 
clinical trials, gemcitabine shows a better tolerable toxicity profile compared to other 
commonly used anticancer drugs. However, a significant variability in its toxicity and 
efficacy resulted in difficulty in toxicity management and treatment optimization. In 
order to improve clinical treatment efficacy and minimize the toxicity of gemcitabine, it 
is essential for scientists to better understand its transportation, activation and metabolism 
pathway. In addition, those functional single-nucleotide polymorphisms in gemcitabine 
disposition pathway will be identified through analyzing genotypic and phenotypic 
association. Membrane transporters are important in drug response as they are major 
determinants of drug absorption, distribution, and elimination. There are two major 
families of NTs: CNT and ENT. Although there are different specificities for these 
transmembrane transporters, gemcitabine has been proven to be the substrate to several of 
them including hENT1, hCNT1 and hCNT2. [107-112]  
Hematological toxicities are the major adverse effects of gemcitabine even though this 
widely used anticancer agent has been thought to be tolerable in most cases. Severe 
neutropenia is usually dose limiting toxicity in clinical setting. [155-157] Gemcitabine 
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triphosphate concentration in the white cell has been used as a surrogate marker to 
evaluate the efficacy and toxicities of gemcitabine due to the difficulty in quantifying 
concentrations of dFdCTP inside tumor tissues. In this chapter, we screened 25 loci 
involved in gemcitabine disposition pathway and further analyzed the association 
between genetic variants and pharmacokinetic parameters of gemcitabine in Asian 
NSCLC patients.  
 
6.2. Objectives 
The main objectives are to comprehensively screen gene SNPs which are thought to play 
an important role on intracellular transportation, metabolism and activation of 
gemcitabine; to correlate the pharmacokinetic parameters of gemcitabine and its 
metabolites with polymorphism of genes involved in pathways of gemcitabine 
transportation, metabolism and activity and to identify genotypic variants associated with 
hematological toxicity, response and survival in Asian patients with advanced non-small 
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6.3. Patients and Methods 
6.3.1. Study population  
In this clinical trial, the study population consisted of 94 healthy volunteers recruited at 
the blood donation clinic and 53 patients with NSCLC receiving treatment for their 
disease in the National University Hospital in Singapore. All patients were newly 
diagnosed cases treated with first-line gemcitabine at 750-1000 mg/m2 on days 1 and 8 
and carboplatin at AUC = 5 mg/ml x min on day 1 every 3 weeks. Among them, 43 
(81%) were Chinese and 10 (19%) were Malays, 36 (68%) were male and the median age 
was 59 years (range 39-74 years). Some 44 (83%) had stage IV disease and 42 (79%) had 
a Kanorfsky Performance Score of ≥ 90. The patients’ eligibility criteria were described 
in detail in previous chapter five. The institutional review board of the National 
University Hospital approved the study and informed consent forms were obtained from 
all subjects. Toxicities were evaluated every cycle using the National Cancer Institute 
Common Toxicity Criteria, version 2.0.  
6.3.2. Blood Sampling 
In pharmacokinetic analysis of dFdCTP, blood samples were collected from 33 patients 
as per described in chapter five. In pharmacogenetic analysis, 8ml of peripheral blood 
was drawn into heparinised vacutainer tubes (Becton Dickinson) from each subject 
before drug treatment and mononuclear cells isolated by Ficoll-Hypaque density gradient 
centrifugation according to manufacturer’s instructions (GE Healthcare, Chalfont St. 
Giles, United Kingdom). DNA was extracted from the mononuclear cells using the 
Puregene DNA purification kit (Gentra Systems, Minneapolis, MN). 
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6.3.3. Quantitation of dFdCTP and Pharmacokinetic Analysis 
The quantitation and pharmacokinetic analysis have been described in Chapter two and 
five, respectively. 
 
6.3.4. Selection of SNP loci 
SNP loci for analysis were identified from publications on genotypes of genes involved 
in gemcitabine transport, metabolism and activity [158-161] and a comprehensive search of 
various public databases: Genecards; (http://www.genecards.org), pharmGKB; 
(http://www.pharmgkb.org), NCBI; (http://www.ncbi.nlm.nih.gov). Candidates were 
selected based on the following priorities (1) their presence in coding regions (2) non-
synonymous coding and (3) reported allele frequencies of greater than 5%. The 
designation of which genotypes were wild type was according to the NCBI database and 
nucleotide numbering began at the translational start site ATG. 
 
6.3.5. Pharmacogenetic analysis 
SNP detection was done by TI lab of Oncology Research Institute. Briefly, 50 ng of DNA 
was amplified in a 25µl reaction containing 1 x FastStart Reaction Buffer, 2mM 
magnesium chloride, 10µM deoxynucleotide mix and 1 unit FastStart Taq Polymerase 
(Roche Diagnostics, Mannheim, Germany) and 5µM each of forward and reverse primers 
obtained either from previous reports or using PSQ Assay design software (Biotage AB, 
Uppsala, Sweden). PCR cycling comprised 4 minutes at 95oC, followed by 40 cycles of 
30 seconds at 95oC, 30secs at the appropriate annealing temperature and 1 min at 72oC, 
before conclusion with a 1 minute at 72oC in a Master Cycler (Eppendorf, Hamburg, 
Germany). 
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PCR products were incubated with 3µl of streptavidin magnetic beads (Amersham 
Pharmacia Biotech, Uppsala, Sweden) and 1x binding buffer (10mM Tris–HCl, 2M 
NaCl, 1mM EDTA, 0.1% Tween 20) and thoroughly mixed for 10min at 37oC. The 
product mix was then denatured by 5 seconds incubation in 0.2M NaOH solution and 
washed in annealing buffer (20mM Tris–acetate, 2mM magnesium acetate) for 10 
seconds. The single-stranded products were transferred to an annealing buffer containing 
15 pmol of the sequencing primer and incubated for 2 min at 80oC in a Hybaid Maxi 14 
hybridization oven (Thermo Electron, USA). Pyrosequencing was then performed on a 
PSQ96MA pyrosequencer instrument (Biotage AB, Uppsala, Sweden) with optimized 
nucleotide dispensation orders. 
 
6.3.6. Statistics 
Compliance with Hardy-Weinberg equilibrium was assessed using Clump software. 
Linkage disequilibrium between gene loci was calculated using exact test a Markov 
chain. The chi-squared test was used to assess differences in the genotype frequency 
between Asians and Caucasians healthy subjects [159-162] as well as associations between 
gene variants and tumor response in NSCLC patients. Associations between hematologic 
toxicity or pharmacokinetic parameters and gene variants were assessed using the Mann-
Whitney test. Kaplan-Meier methods and log-rank test were used to compare overall 
survival and time to progression. Cox proportional hazards models were used to adjust 
for stage and performance status. All statistical tests were two-sided and SPSS software 
version 13.0 (SPSS Inc, Chicago, IL) was used. A p value of less than 0.05 was 
considered to indicate statistical significance. 
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6.4. Results 
6.4.1. Distribution of gemcitabine pathway genotypes in healthy Caucasians and 
Asians 
An extensive search of publications and genome databases on sequence variants in genes 
encoding proteins involved in pathways of gemcitabine transport, metabolism and 
activity identified 25 loci in 9 genes that qualified for analysis (see Figure 6.1.). 
 
Figure 6.1 Selection of Gene loci involved in pathways of gemcitabine transport, 
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Pyrosequencing enabled genotyping of all 25 loci in all 94 healthy Asian donors 
including 57 (61%) Chinese, 20 (21%) Malay and 17 (18%) Indian. The Primers, PCR 
annealing temperatures and dispensation sequences and used for genotyping in this study 
were listed as follows (Table 6.1). 
 
 
Table 6.1 Primers, PCR annealing temperatures and dispensation sequences used 


















The frequency of each genotype with variation (19 SNPs) is depicted in Figure 6.2.  
 
 
Figure 6.2 Difference in sequence variants distribution between 94 healthy Asians 
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All gene frequencies were in Hardy-Weinberg equilibrium. There was no sequence 
variation at 6 gene loci (CDA+208, RRM1+17, RRM1+5 36, RRM1+589, RRM1+2333, 
and SLC29A1+600), hence these loci were excluded from further analysis. The following 
gene loci pairs were in linkage disequilibrium: CDA+79 and CDA+435 (r2=0.209), 
RRM1 (-756) and RRM1 (-269) (r2=0.905), SLC28A2+65 and SLC28A2+225 
(r2=0.937), SLC28A1+565 and SLC28A1+709 (r2=0.608), SLC28A1+1528 and 
SLC28A1+1561 (r2=0.601). 
Comparison of the genotype distributions of the Asian populations assessed in this study 
with those reported from Caucasians showed difference in 10/19 (53%) loci between 
Caucasians and Chinese, 10/19 (53%) between Caucasians and Malays and 7/19 (37%) 
between Caucasians and Indians (Figure 6.2.). There were no significant differences 
among genotype distributions for Asians (Chinese, Malays and Indians combined) in this 
study and those reported previously. [158-161] 
 
6.4.2. Impact of hCNT2 Polymorphism on Neutropenia  
Grade 3/4 neutropenia frequencies of gemcitabine in combination with carboplatin were 
found to associate strongly with sex in our previous phase I trial with 15 subjects. [15] In 
this current phase II study, we further tested if sex was still an important determinant on 
hematological toxicity with a much larger sample size (n = 58) using nonparametric test 
(Mann Whitney test). The results showed that there was a strong association between sex 
and neutrophil nadir (Figure 6.3).  
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Figure 6.3 Effect of sex on neutrophil nadir to gemcitabine treatment 
 
 
Baseline neutrophil counts between male and female subjects were comparable. The 
average counts for males and females were 6.60 ± 2.75 and 6.09 ± 3.84 respectively. No 
significant difference was detected by using t-test (p = 0.63) as well as Mann Whitney 
test (p = 0.78). However, female subjects had significant lower nadir neutrophil counts 
than those of male subjects after chemotherapy. 
In order to answer why sex could result in a significant difference on neutropenia, 
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6.4.2.1. The Effect of Sex on Pharmacokinetics of Gemcitabine  
Pharmacokinetic analysis was performed using WinNonLin version 5.2 (Pharsight Inc., 
Mountain View, California, USA). Non compartmental analysis was used to estimate the 
pharmacokinetic parameters. The terminal portion of the curve was determined by 
extrapolation of the log –linear concentration –time curve to infinity and regression of the 
last three points of the curve without weighting.  
The important pharmacokinetic parameters like AUC, Cmax and Cl of gemcitabine and 
dFdCTP as well as AUC ratio of dFdU/gemcitabine were compared between males and 
females but no significant difference was detected [e.g. the average AUC0-inf of 
gemcitabine (1287.60 ± 541.22 µM*min) for females vs males (1437.94 ± 981.83 
µM*min) was not significantly different (p = 0.56, t-test)].  
 
6.4.2.2. Phenotypic and Genotypic analysis  
Since neutropenia is a very common adverse effect during gemcitabine treatment, we 
only selected those SNPs which possess more than 10% frequency both for males and 
females. In addition, we focused on evaluating those SNPs with more than 2-fold 
difference between males and females. According to these two criteria, only two SNPs 
within one gene, SLC28A2+65 and SLC28A2+225, were selected as our study target 
SNPs (Figure 6.4).   
 
Chapter VI:  Genotypic and Phenotypic Association of Gemcitabine 
 150
 
Figure 6.4 SNPs distribution between males and females     
Both SLC28A2+65 C>T and SLC28A+225 C>A variants were associated with neutrophil 
nadir. For SLC28A2+65 C>T variants, patients with CC genotypes had a higher median 
neutrophil nadir than those with CT/TT genotypes (0.82 x109 cells/L and 0.46 x109 
cells/L respectively, p=0.021) (Figure 6.5, left). For SLC28A+225 C>A variants, the 
median neutrophil nadir for genotypes CC vs CA/AA was 0.82 x109 cells/L and 0.46 x109 
cells/L respectively (p=0.049) (Figure 6.5, right) 
 
 
Figure 6.5 Association of SLC28A2+65 C>T (left) and SLC28A2+225 C>A 
(right) with neutrophil nadir 
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In addition, these two variants in SCL28 were also associated with patients’ survival. The 
median overall survival of patients with the CC genotype was 8.2 (5.7-10.3) months and 
for CT/TT genotypes 18.3 (11.6-25.0) months (p=0.001) (Figure 6.6 left). The median 
overall survival in patients with CC and CA/AA genotypes was 8.5 (6.2-10.8) months and 





Figure 6.6 Association of SLC28A2+65 C>T (left) and SLC28A2+225 C>A 
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In separate multivariate analyses, both SLC28A2+65 CT/TT (Hazard Ratio = 0.31 [95% 
confidence interval = 0.15-0.65], p=0.002) and SLC28A+225 CA/AA (0.35 [0.17-0.71], 
p=0.004) genotypes were independently associated with improved overall survival after 
adjusting for stage and performance status. With both genotypes, stage and performance 
status entered, SLC28A2+65 CT/TT (0.09[0.01-0.84], p=0.035) was the only 
independent variable. 
Neutropenia frenquency and survival of NSCLC patients in gemcitabine and carboplatin 
combination therapy are mainly dependent on genetic variants on human SLC28A2 
(hCNT2) according to our systematic genetic screening on gemcitabine genetic pathways. 
Although sex seemed to have an important impact on neutropenia (Figure 6.7), with data 
showing significant differences in grade 0 and grade 4 neutropenia between males and 
females in 53 subjects, this influence could not be supported when the frequency analysis 











  Figure 6.7 Comparison between neutropenia grade and frequency  





Figure 6.8 Comparison between neutropenia grade and frequency  
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6.5. Discussion 
Studies have identified various gene polymorphisms that are associated with outcome and 
toxicity in patients with NSCLC. Recently, a polymorphism in the gene uridine 
diphosphate-glucuronosyltransferase 1A1 was associated with toxicity and survival in 
NSCLC patients treated with irinotecan-based chemotherapy has been reported.[163] To 
our knowledge, our study is the first to systematically assess the association between 
gemcitabine transport pathway gene polymorphisms with clinical outcome in NSCLC 
patients receiving gemcitabine-based chemotherapy. 
The frequency of gene variants involved in the gemcitabine pathway has been previously 
reported in the healthy Caucasians [158] whereas data on Asian subjects have been limited 
to genes involved in the gemcitabine transport, SLC28A1, SLC28A2 [159, 161]and 
ribonucleotide reductase.[160] Our study contributes further to the literature by providing 
data on healthy Chinese, Indian and Malay subjects. No significant differences among the 
Asians with regards to genotypes distribution were found in our study. However we did 
find a significant difference in the distribution of up to 10 gene loci between healthy 
ethnic Asians and the Caucasian population.  
Gemcitabine is a prodrug and its efficacy is highly dependent on intracellular drug 
concentration of dFdCTP. Some pioneer work in gemcitabine study showed that dFdCTP 
concentration in the peripheral leucocytes might be used as a surrogate marker to 
evaluate the efficacy and toxicities to gemcitabine treatment since dFdCTP was the major 
intracellular active metabolite (85-90%). [12, 47] Due to the difficulty in harvesting, sample 
preparation and quantification of dFdCTP concentrations in clinical samples, very few 
results were available on clinical pharmacokinetic studies of intracellular dFdCTP. Our 
Chapter VI:  Genotypic and Phenotypic Association of Gemcitabine 
 155
PK analysis did not show significant relationship between intracellular dFdCTP PK and 
the selected transporter genetic variants studied. 
Sex seemed to influence neutropenia in our 53 NSCLC patients during their 
chemotherapy with gemcitabine and carboplatin combination therapy but no difference 
on neutropenia severity and frequencies were formed between males and females in the 
hCNT2 cohort. This strongly suggested that genetic variants but not sex would be a 
determinant factor in neutropenia and survival for infusion gemcitabine based therapies. 
Our data showed that both SLC28A2+65 C>T and SLC28A+225 C>A variants were 
significantly associated with neutrophil nadir and survival as well. Two adjacent amino 
acid changes in 2 SNPs variants could change substrate specificity of hCNT2. Previously 
even though hCNT2 was not regarded to be selective for pyrimidine nucleoside 
substrates, it has been identified as one of gemcitabine transporters according to latest 
research findings. [113, 117] Herein, we proposed that hCNT2 mutations (SLC28A2+65 
C>T and SLC28A+225 C>A) could be potential genetic markers for better survival and 
more severe neutropenia to gemcitabine treatment. The reasons for high impact of 
hCNT2 on gemcitabine neutropenia and survival may be due to the change of substrate 
specificity of hCNT2 when mutations take place. Under normal physiological conditions, 
gemcitabine is mainly transported through hCNT1 and hCNT3 due to their substrate 
specificities for pyrimidine nucleosides. Under this condition, the effect of hCNT2 on 
gemcitabine’s intracellular transportation could be negligible. However, when hCNT2 
mutates, its impact on gemcitabine intracellular accumulation would be dramatically 
increased. Thus, this could result in a significant increase of dFdCTP concentration in 
hCNT2 mutant subjects since both variants of SLC28A2+65 C>T and SLC28A2+225 
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C>A are located in coding region of this transport gene. [161] Therefore, this genetic 
marker on hCNT2 could be very useful for oncologists to individualize patient treatment 
as patients with SLC28A2+65 C>T and SLC28A2+225 C>A would be expected to have a 
significant benefit on survival. In the mean while, this group of patients may also 
experience higher riskes of severe neutropenia. This genetic variant-drug response marker 
would have a greater clinical implication if it could be validated with a larger population. 
SLC28A2 +65 C>T variants were significantly lower in Chinese (12%) and Malays 
(55%) compared with Caucasians (63%) whereas the frequency of SLC28A2 +225 C>A 
variants was lower in the Chinese (12%) compared with Caucasians (55%). Based on the 
differences in the distribution of these gene variants, we speculated that Asians may have 
a lower risk of hematological toxicity but also a lower overall survival through 
gemcitabine treatment. The effect of ethnicity on gemcitabine pharmacology should be 
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6.6. Conclusions 
Although the genetic distribution of gemcitabine activation pathway related genes have 
been studied intensivly in Caucasians, less information is available for Asians. A systemic 
screening of genetic polymorphism was processed in our study for understanding genetic 
distribution in healthy Asian population; ten gene loci were found to be significantly 
different in the distribution of genotypes between Asians and Caucasians among 25 
SNPs.  
Sex seemed to have some impact on hematological toxicities to gemcitabine treatment in 
our Phase I clinical trial and a larger scale clinical Phase II study. However, this influence 
of sex was found to be not important factor in our study. Instead, SNPs in hCNT2 were 
identified as a potential determinant on hematological toxicities and patient survival in 
gemcitabine treatment combined with carboplatin although no pharmacokinetic 
differences were detected between wild-type and variants of hCNT2. With current 
advanced gene screening technique, it would be very convenient and fast to analyze the 
SNPs in hCNT2 for NSCLC patients in gemcitabine based treatment. This could provide 
oncologists with valuable information for individual patient’s treatment. Nevertheless, a 
larger clinical trial would be necessary to further validate our current findings.  
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In this thesis on Pharmacology of gemcitabine in the Asian Population, bioanalytical 
methods for accurate, reliable and precise quantitation of plasma gemcitabine and dFdU 
as well as intracellular dFdCTP formed the essence for the studies. These methods were 
successfully developed and validated. 
The chapter on in vitro study demonstrated that exposure time above 2 µM gemcitabine 
was an important factor for achieving cytotoxic effects on HONE1 cells. In addition, 
gemcitabine resistance can be overcome by novel combination therapies, e.g. 
gemcitabine plus PXD101.  
For the clinical studies, the initial dose finding trial for fixed rate infusion of 10 
mg/m2/min gemcitabine indicated that 75 min infusion (total dose of 750 mg/m2) was 
tolerable for Asian patients. This fixed rate schedule was selected as arm A for 
comparison with arm B, the standard 30 min infusion of 1000mg mg/m2 in the later phase 
II trial. The results showed no significant differences between the two arms with regards 
to pharmacokinetic parameters, patients’ toxicities and clinical efficacy even though there 
was a 25% lower total dose of gemcitabine at the fixed rate infusion schedule. One 
interesting indication found was that the metabolite/parent (dFdU/gemcitabine) ratios at 
120 min were highly related to early phase response rate according to RECIST criteria. 
The ratios of dFdU/gemcitabine at 120 min for non-responders were significantly higher 
than those of the responders. Ratios larger than 500 seemed to predict that the patient 
would be a non-responder in the early phase treatment cycle to gemcitabine.  
Finally, the genetic status in hCNT2 was identified as a determinant of hematological 
toxicities and survival in treatment with gemcitabine in combination with carboplatin 
through pharmacogenetic and pharmacodynamic association. The patients with genetic 
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variants both in SLC28A2+65 C>T and SLC28A2+225 C>A would have a longer 
survival but also could experience more serious toxicities than those with wild-type. 
Genetic screening for hCNT2 could be a useful clinical disease progression marker.  
Both the dFdU/gemcitabine ratios at 120 min as a potential predictor for early phase 
response as well as the patients’ genetic status of hCNT2 as a useful marker for toxicities 
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